Hashimoto's Thyroiditis

Complex MONDO:0007699 Pathograph 35 Show in embeddings browser Autoimmune Disease Endocrine Disease

Hashimoto's thyroiditis is a chronic autoimmune disease and the leading cause of primary hypothyroidism, in which loss of immune tolerance to thyroid antigens (thyroid peroxidase and thyroglobulin) drives lymphocytic infiltration and progressive destruction of thyroid follicular cells. CD4 and CD8 T cells together with anti-TPO and anti-thyroglobulin autoantibodies deplete the gland, producing thyroid hormone deficiency that manifests as fatigue, weight gain, cold intolerance, and goiter. Susceptibility is conferred by HLA and other immune-regulatory loci interacting with environmental triggers such as iodine excess and viral infection, and levothyroxine replacement reverses the hypothyroid syndrome.

Ask OpenScientist

Ask a research question about Hashimoto's Thyroiditis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

10
Pathophys.
11
Phenotypes
1
Hypotheses
35
Pathograph
7
Genes
4
Medical Actions
1
Datasets
3
References
2
Deep Research
1
Hyp. Reports
🏷

Classifications

Harrison's Part
ENDOCRINOLOGY METABOLISM IMMUNE RHEUMATOLOGIC
C

Comorbidities

Autoimmune Gastritis <-> Hashimotos Thyroiditis
Disease B BIDIRECTIONAL CANDIDATE
◈

Mechanistic Hypotheses

1
Canonical Autoimmune Thyrocyte Destruction Model
canonical_autoimmune_thyrocyte_destruction_model CANONICAL
Evidence balance 1 support
Hashimoto's thyroiditis is a chronic autoimmune disease in which loss of immune tolerance to thyroid antigens — primarily thyroid peroxidase (TPO) and thyroglobulin (Tg) — drives lymphocytic infiltration of the thyroid gland, formation of intrathyroidal tertiary lymphoid structures, and progressive thyrocyte destruction. CD4 Th1 and Th17 cells, CD8 cytotoxic T cells, and autoantibody- mediated effects (anti-TPO, anti-Tg) act together to deplete follicular cells, producing primary hypothyroidism. Susceptibility is conferred by HLA-DR3/DR5, CTLA4, PTPN22, and other immune- regulation loci, with environmental triggers including iodine excess, viral infection, and selenium deficiency. Levothyroxine replacement reverses the hypothyroid syndrome by bypassing the destroyed gland, supporting glandular failure as the proximate clinical lesion in this canonical model.
Retained as CANONICAL. The 2026 openscientist hypothesis-search report (kb/hypotheses/Hashimotos_Thyroiditis/canonical_autoimmune_thyrocyte_destruction_model) confirms 12 of 13 mechanistic claims as established. Core effector mechanisms — Fas/FasL-mediated thyrocyte apoptosis (sensitized by IFN-γ + IL-1β, independent of perforin/granzyme), intrathyroidal tertiary lymphoid structures functioning as germinal centers with RAG1/RAG2 in situ receptor revision, and coordinated CD4 Th1/Th17 + CD8 + autoantibody (anti-TPO in >90%) responses — are validated by histopathology, single-cell transcriptomics, and immune-checkpoint-inhibitor-induced thyroiditis as a natural experiment. JAK inhibition has provided proof-of-concept reversal. Six refinements: (1) Th17/Treg imbalance is now established as an upstream initiator preceding Th1-mediated destruction, not captured by the seed description; (2) IgG4-related thyroiditis (~27%) and seronegative HT (~12%) are clinically significant subtypes the model does not address; (3) GWAS identifies 418 independent signals (vs ~5 canonical loci) explaining only ~5.4% of variance, indicating extensive polygenicity; (4) the gut- thyroid axis (molecular mimicry, SCFA depletion) provides a mechanistic bridge from environmental triggers to immune dysregulation; (5) thyrocyte HLA class II expression (Bottazzo hypothesis) and NETosis are increasingly implicated; (6) sex-specific intrathyroidal B-cell homing via CXCL13-CXCR5 helps explain the female predominance. The initial tolerance-breaking event remains unknown and no disease- modifying RCT has yet been completed.
Deep research
OpenScientist citations 41 citations 2026-05-23T22:25:33.576575
Show evidence (1 reference)
PMID:38731922 SUPPORT Human Clinical
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Canonical mechanism reference used as the seed for the hypothesis-search deep-research run. It supports the autoantibody plus lymphocytic-infiltration core of the model, but not the full CD4 Th1/Th17, CD8, tertiary-lymphoid-structure, or genetic-susceptibility claims in the hypothesis description.
⚙

Pathophysiology

10
Thyroglobulin Hyperiodination and Neoantigen Formation
Excess iodide drives heavier iodination of thyroglobulin during hormone synthesis, and the more heavily iodinated protein carries altered epitopes that are more immunogenic than lightly iodinated Tg. This iodine-dependent neoantigen state is the proximate biochemical step through which chronic iodine excess presents modified self-antigen to the immune system, and is the intermediate node inserted between the iodine-excess exposure and the loss of tolerance.
Thyroid Follicular Cell CL:0002258 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Thyroid Follicular Cell (CL:0002258). CL:0002258 is a cell type from the Cell Ontology.
Thyroglobulin iodination GO:0006590 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal Thyroglobulin iodination, annotated with thyroid hormone generation (GO:0006590). GO:0006590 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Loss of Immune Tolerance to Thyroid Antigens Presentation of the more immunogenic hyperiodinated thyroglobulin promotes autoreactive recognition of thyroid self-antigen, contributing to the breakdown of tolerance.
Show evidence (1 reference)
PMID:28290237 SUPPORT Human Clinical
"Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin (Tg) is more immunogenic."
Names highly iodinated thyroglobulin as the more immunogenic species, identifying the intermediate biochemical state linking iodine excess to the autoimmune response.
Thyroidal Oxidative Stress from Selenoprotein Insufficiency
Thyroid hormone synthesis generates hydrogen peroxide at the apical thyrocyte surface, which selenoprotein glutathione peroxidases normally detoxify. When selenium supply is low these selenoenzymes are limiting, so peroxide accumulates and oxidatively injures thyroid follicular cells. This oxidative thyrocyte injury and antigen release is the mechanism node downstream of the "Selenium Deficiency" state and upstream of the loss of tolerance.
Thyroid Follicular Cell CL:0002258 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Thyroid Follicular Cell (CL:0002258). CL:0002258 is a cell type from the Cell Ontology.
Peroxide detoxification by glutathione peroxidase GO:0042744 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Peroxide detoxification by glutathione peroxidase, annotated with hydrogen peroxide catabolic process (GO:0042744). GO:0042744 is a biological process from the Gene Ontology. ↓ DECREASED Response to oxidative stress GO:0006979 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Response to oxidative stress (GO:0006979). GO:0006979 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Loss of Immune Tolerance to Thyroid Antigens Oxidative thyrocyte injury releases and modifies sequestered thyroid antigens, promoting autoreactive priming and loss of tolerance.
Show evidence (2 references)
PMID:28290237 SUPPORT Human Clinical
"the glutathione peroxidases protect the thyroid by removing excessive hydrogen peroxide produced for Tg iodination"
Identifies selenoprotein glutathione peroxidases as the thyroid's defense against the hydrogen peroxide of hormone synthesis, so their insufficiency in selenium deficiency leaves the gland exposed to oxidative injury.
PMID:35789269 SUPPORT Human Clinical
"The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
Prospective cohort evidence that low selenium status raises the incidence of thyroid autoantibody seroconversion, linking this oxidative-stress state to onset of autoimmunity.
Impaired Vitamin D-Dependent Immune Tolerance
Vitamin D signaling supports tolerogenic dendritic cells and regulatory T-cell function, an immunomodulatory brake that favors self-tolerance. Low vitamin D status weakens this brake and is proposed to permit escape from immune regulation. The direction of this association is unsettled: the cited cross-sectional finding is that levels are lower in people who already have the disease, and part of the same nutritional-risk literature attributes the low levels to the autoimmune process itself (including vitamin D receptor dysfunction) rather than the reverse.
Immune tolerance induction GO:0002507 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Immune tolerance induction, annotated with tolerance induction (GO:0002507). GO:0002507 is a biological process from the Gene Ontology. ↓ DECREASED Regulation of immune response GO:0050776 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Regulation of immune response (GO:0050776). GO:0050776 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Loss of Immune Tolerance to Thyroid Antigens Weakened vitamin D-dependent immunoregulation is proposed to lower the threshold for loss of tolerance to thyroid antigens, though the causal direction is not established.
Show evidence (2 references)
PMID:38542128 SUPPORT Human Clinical
"Vitamin D carries out an immunomodulatory role that appears to promote immune tolerance."
States vitamin D's immunomodulatory, tolerance-promoting role, the basis for treating its deficiency as a state of weakened immune regulation.
PMID:38542128 SUPPORT Human Clinical
"Hashimoto's thyroiditis (HT) is marked by self-tissue destruction as a consequence of an alteration in the adaptive immune response that entails the evasion of immune regulation."
Frames HT as evasion of immune regulation, the tolerance failure that impaired vitamin D-dependent immunomodulation is proposed to promote.
Hepatitis C Virus-Associated Thyroid Immune Activation
The specific virus with human evidence here is hepatitis C virus (HCV; chronic HCV infection, MONDO:0005354), which is associated with thyroid autoimmunity and hypothyroidism. Molecular mimicry between viral and thyroid antigens and bystander activation of autoreactive lymphocytes are the usual mechanistic proposals, but the cited evidence is an epidemiological association, and interferon-based antiviral therapy for HCV is itself thyrotoxic, which confounds it. This HCV-associated immune-activation state is the intermediate node between the HCV-infection exposure and the loss of tolerance.
Defense response to virus GO:0051607 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Defense response to virus (GO:0051607). GO:0051607 is a biological process from the Gene Ontology.
Downstream
Loss of Immune Tolerance to Thyroid Antigens Antiviral immune activation is proposed to break tolerance to thyroid antigens via molecular mimicry or bystander activation, a mechanism not established by the cited association.
Show evidence (1 reference)
PMID:32107168 SUPPORT Human Clinical
"Many studies showed that HCV is associated with thyroid autoimmunity and hypothyroidism, in patients with chronic HCV hepatitis (CHC); a significant link has been shown also between HCV-related mixed cryoglobulinemia and risk for GD."
Reports the epidemiological association of chronic HCV infection with thyroid autoimmunity and hypothyroidism, the observation behind this HCV-associated immune-activation state.
Loss of Immune Tolerance to Thyroid Antigens
Susceptibility variants in T-cell regulatory and immune-checkpoint genes (HLA class II, CTLA4, PTPN22, LAG3) act together with environmental triggers (iodine excess, selenium/vitamin D status, viral infection) to break self-tolerance to thyroid peroxidase and thyroglobulin, the initiating lesion that licenses autoreactive T- and B-cell responses against the thyroid. A rare LAG3 start-codon variant that lowers the inhibitory checkpoint LAG-3 exemplifies how impaired T-cell down-regulation predisposes to autoimmune thyroid disease.
CTLA4 hgnc:2505 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CTLA4 (hgnc:2505). hgnc:2505 is a gene from the HUGO Gene Nomenclature Committee. PTPN22 hgnc:9652 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PTPN22 (hgnc:9652). hgnc:9652 is a gene from the HUGO Gene Nomenclature Committee. LAG3 hgnc:6476 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves LAG3 (hgnc:6476). hgnc:6476 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Thyrocyte Antigen Presentation Breakdown of tolerance permits autoreactive T cells and an interferon-rich milieu that drives thyroid follicular cells to present antigen.
Lymphocytic Infiltration Loss of tolerance licenses autoreactive T and B lymphocytes that traffic into and accumulate within the thyroid gland.
Show evidence (1 reference)
PMID:38982041 SUPPORT Human Clinical
"Multiomics analysis yields 235 candidate genes outside the MHC-region and the findings highlight the importance of genes involved in T-cell regulation."
A large AITD GWAS meta-analysis localizes susceptibility to T-cell regulatory genes, supporting loss of T-cell tolerance as the initiating mechanism.
Thyrocyte Antigen Presentation
Under interferon-gamma and TNF-alpha exposure, thyroid follicular cells aberrantly upregulate MHC class II together with the invariant chain CD74 and its ligand MIF, becoming non-professional antigen-presenting cells. This amplifies local antigen presentation and ligand-receptor cross-talk with infiltrating immune cells, sustaining and propagating the intrathyroidal autoimmune response.
Thyroid Follicular Cell CL:0002258 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Thyroid Follicular Cell (CL:0002258). CL:0002258 is a cell type from the Cell Ontology.
Antigen presentation via MHC class II GO:0002495 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Antigen presentation via MHC class II, annotated with antigen processing and presentation of peptide antigen via MHC class II (GO:0002495). GO:0002495 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Lymphocytic Infiltration Thyrocyte antigen presentation and chemokine expression recruit and activate infiltrating lymphocytes within the gland.
Show evidence (1 reference)
PMID:39003267 SUPPORT Human Clinical
"We identify damaged antigen-presenting TFCs with upregulated CD74 and MIF expression in thyroid samples from AITD patients."
Spatial transcriptomics shows thyroid follicular cells act as antigen-presenting cells via CD74/MIF upregulation, driving local autoimmunity.
Artifact: image-1.png
image-1.png
Autoimmune Thyroid Destruction
T cell-mediated and antibody-mediated destruction of thyroid follicular cells leads to progressive loss of thyroid function. Anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies are characteristic.
Thyroid Epithelial Cell CL:0002257 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Thyroid Epithelial Cell, annotated with epithelial cell of thyroid gland (CL:0002257). CL:0002257 is a cell type from the Cell Ontology. T Helper Cell CL:0000492 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves T Helper Cell, annotated with CD4-positive helper T cell (CL:0000492). CL:0000492 is a cell type from the Cell Ontology.
Autoimmune Response GO:0002460 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Autoimmune Response, annotated with adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains (GO:0002460). GO:0002460 is a biological process from the Gene Ontology.
Downstream
Thyroid Hormone Deficiency Progressive cytotoxic and antibody-mediated loss of hormone-producing follicular cells depletes the gland's capacity to synthesize T3 and T4, producing thyroid hormone deficiency.
Hashitoxicosis Early inflammatory destruction of follicles can release preformed stored hormone, producing a transient thyrotoxic (hashitoxicosis) phase before glandular reserve is exhausted and hypothyroidism supervenes.
Show evidence (3 references)
PMID:39003267 SUPPORT Human Clinical
"We identify damaged antigen-presenting TFCs with upregulated CD74 and MIF expression in thyroid samples from AITD patients."
Spatial transcriptomics demonstrates that thyroid follicular cells actively participate in autoimmune destruction by presenting antigens via CD74/MIF upregulation.
PMID:38731922 SUPPORT Human Clinical
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Confirms the characteristic antibody profile and lymphocytic infiltration pattern in Hashimoto's thyroiditis.
PMID:40535343 SUPPORT Human Clinical
"Through this review, we aim to establish mechanistic connections between ICI pharmacodynamics and thyroid tissue immunopathology."
ICI-induced thyroiditis provides a mechanistic model that mirrors the autoimmune destruction seen in spontaneous Hashimoto's thyroiditis.
Lymphocytic Infiltration
Dense lymphocytic infiltration of the thyroid gland with germinal center formation. CD4+ T cells, CD8+ T cells, and B cells accumulate in the thyroid parenchyma.
CD4-positive helper T cell CL:0000492 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD4-positive helper T cell (CL:0000492). CL:0000492 is a cell type from the Cell Ontology. CD8-positive, alpha-beta T cell CL:0000625 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD8-positive, alpha-beta T cell (CL:0000625). CL:0000625 is a cell type from the Cell Ontology. B Cell CL:0000236 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves B Cell (CL:0000236). CL:0000236 is a cell type from the Cell Ontology.
Inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. Adaptive immune response GO:0002250 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Adaptive immune response (GO:0002250). GO:0002250 is a biological process from the Gene Ontology.
Downstream
Autoimmune Thyroid Destruction Infiltrating cytotoxic T cells, autoantibody-producing B/plasma cells, and inflammatory macrophages execute follicular-cell killing.
Goiter Dense inflammatory infiltration and lymphoid-follicle formation enlarge the gland, producing the characteristic diffuse goiter.
Show evidence (2 references)
PMID:38731922 SUPPORT Human Clinical
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Lymphocytic infiltration is a defining histological feature of Hashimoto's thyroiditis.
PMID:39003267 SUPPORT Human Clinical
"Here, we use spatial transcriptomics to explore the molecular architecture, heterogeneity and location of different cells present in the thyroid tissue, including thyroid follicular cells (TFCs), stromal cells such as fibroblasts, endothelial cells, and thyroid infiltrating lymphocytes."
Spatial analysis confirms the presence and organization of infiltrating lymphocytes in the thyroid microenvironment.
NF-κB-IL-6 Signaling Pathway Activation
Genetic regulation of NF-κB and IL-6 signaling modulates the autoimmune response in Hashimoto's thyroiditis. CCDC77 and SLC45A3 are novel genetic modifiers that regulate NF-κB pathway activation and IL-6 production. CCDC77 acts as a protective regulator (knockdown exacerbates thyroid damage), while SLC45A3 acts as a disease-promoting factor (knockdown alleviates thyroiditis). The NF-κB-IL-6 axis modulates immune cell activation and thyroid-targeted autoimmunity.
Macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
NF-κB signaling pathway GO:0007249 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves NF-κB signaling pathway, annotated with canonical NF-kappaB signal transduction (GO:0007249). GO:0007249 is a biological process from the Gene Ontology. Inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology.
Downstream
Lymphocytic Infiltration Genetic modulation of the NF-κB-IL-6 axis tunes immune-cell activation and recruitment, amplifying the intrathyroidal lymphocytic infiltrate.
Show evidence (2 references)
PMID:42283571 SUPPORT Human Clinical
"MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
Two-sample Mendelian randomization using human eQTL/GWAS data identified CCDC77 and SLC45A3 as IL-6-linked genes associated with Hashimoto's thyroiditis.
PMID:42283571 SUPPORT Model Organism
"In vivo experiments showed that knockdown of CCDC77 exacerbated thyroid damage, increased serum anti-thyroperoxidase antibody (TPOAb), anti-thyroglobulin antibody (TGAb), and IL-6 levels, while reduced free triiodothyronine (FT3) and free thyroxine (FT4). Conversely, SLC45A3 knockdown alleviated..."
In vivo validation in NOD mice demonstrates that CCDC77 and SLC45A3 regulate HT progression through the NF-κB-IL-6 signaling axis; CCDC77 is a protective modulator while SLC45A3 is disease-promoting.
Thyroid Hormone Deficiency
Progressive destruction of thyroid tissue leads to decreased production of T3 and T4, resulting in hypothyroidism with elevated TSH through negative feedback.
Thyroid Hormone Synthesis GO:0006590 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Thyroid Hormone Synthesis, annotated with thyroid hormone generation (GO:0006590). GO:0006590 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Hypothyroidism Insufficient T3/T4 output with compensatory TSH elevation manifests clinically as primary hypothyroidism.
Show evidence (1 reference)
PMID:38731922 SUPPORT Human Clinical
"Due to the progressive destruction of cells, AITD can lead to subclinical or overt hypothyroidism."
Progressive thyroid destruction in Hashimoto's thyroiditis results in hypothyroidism through loss of hormone-producing cells.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hashimoto's Thyroiditis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Digestive 1
Constipation FREQUENT HP:0002019 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Constipation (HP:0002019). HP:0002019 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35235282 SUPPORT Human Clinical
"Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
Constipation is a recognized symptom in hypothyroid states.
Endocrine 3
Goiter FREQUENT HP:0000853 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Goiter (HP:0000853). HP:0000853 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38731922 SUPPORT Human Clinical
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Goiter develops due to lymphocytic infiltration and inflammatory enlargement of the thyroid gland.
Hypothyroidism HP:0000821 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypothyroidism (HP:0000821). HP:0000821 is a phenotype from the Human Phenotype Ontology.
Sequelae: Fatigue Weight Gain Cold Intolerance Dry Skin Constipation Depression
Show evidence (1 reference)
PMID:32805423 SUPPORT Human Clinical
"developing a primary hypothyroidism"
This review states Hashimoto thyroiditis develops a primary hypothyroidism.
Hashitoxicosis Hyperthyroidism HP:0000836 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hashitoxicosis (transient hyperthyroidism), annotated with Hyperthyroidism (HP:0000836). HP:0000836 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24434360 SUPPORT Human Clinical
"at presentation patients can be euthyroid or even hyperthyroid"
This clinical-criteria review notes patients may be hyperthyroid at presentation of Hashimoto thyroiditis.
Integument 1
Dry Skin FREQUENT HP:0000958 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dry Skin (HP:0000958). HP:0000958 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35235282 SUPPORT Human Clinical
"Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
Dry skin is a common dermatologic manifestation of hypothyroidism.
Metabolism 1
Cold Intolerance FREQUENT HP:6000855 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cold Intolerance (HP:6000855). HP:6000855 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35235282 SUPPORT Human Clinical
"Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
Cold intolerance is a common symptom of hypothyroidism in Hashimoto's thyroiditis.
Nervous System 1
Depression HP:0000716 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Depression (HP:0000716). HP:0000716 is a phenotype from the Human Phenotype Ontology.
Frequency band deliberately omitted: the only cited source lists depression among the "most common presenting symptoms", which conflicts with the previously curated OCCASIONAL (5-29%) band and provides no quantitative estimate. Per the frequency-evidence guidelines, no band is asserted.
Show evidence (1 reference)
PMID:23744563 SUPPORT Human Clinical
"The most common presenting symptoms may include anxiety, negative mood, depression, dry skin, cold intolerance, puffy eyes, muscle cramps and fatigue, deep voice, constipation, slow thinking and poor memory."
Depression is reported among common presenting symptoms in Hashimoto's thyroiditis.
Constitutional 1
Fatigue VERY_FREQUENT HP:0012378 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fatigue (HP:0012378). HP:0012378 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35235282 SUPPORT Human Clinical
"Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
Hashimoto-associated hypothyroidism commonly presents with fatigue.
Growth 1
Weight Gain FREQUENT Increased body weight HP:0004324 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Weight Gain, annotated with Increased body weight (HP:0004324). HP:0004324 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35235282 SUPPORT Human Clinical
"Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
Weight gain is a common hypothyroid symptom in Hashimoto's thyroiditis.
Other 2
Vitamin D Deficiency Decreased circulating vitamin D concentration HP:0100512 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Vitamin D deficiency, annotated with Decreased circulating vitamin D concentration (HP:0100512). HP:0100512 is a phenotype from the Human Phenotype Ontology.
HP:0100512 is bound here as an upstream risk state, not a manifestation: because this phenotype has a sequelae edge into a pathophysiology node, the KGX/HPOA exporters export it as a direction-neutral `MONDO:0007699 biolink:associated_with HP:0100512` rather than `has_phenotype`. (This supersedes the earlier workaround of binding MONDO:0100471 to dodge the has_phenotype inversion; the direction-aware exporter makes the HP binding correct.) The association is cross-sectional and may be bidirectional; part of the nutritional-risk literature (PMID:28290237) attributes low vitamin D to the autoimmune process itself, including vitamin D receptor dysfunction.
Sequelae: Impaired Vitamin D-Dependent Immune Tolerance
Show evidence (1 reference)
PMID:38542128 SUPPORT Human Clinical
"There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people."
Grounds the vitamin D-deficiency state as a finding associated with HT.
Selenium Deficiency Decreased circulating selenium concentration HP:0033192 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Selenium deficiency, annotated with Decreased circulating selenium concentration (HP:0033192). HP:0033192 is a phenotype from the Human Phenotype Ontology.
HP:0033192 is bound here as an upstream risk state, not a manifestation. The KGX/HPOA exporters detect that (this phenotype has a sequelae edge into a pathophysiology node) and export it as a direction-neutral `MONDO:0007699 biolink:associated_with HP:0033192` rather than `has_phenotype`, so the export does not invert the cited prospective cohort in which low selenium supply *precedes* TPO-Ab seroconversion. MONDO has no human selenium-deficiency class (MONDO:1017720 is explicitly non-human-animal, MONDO:0000241 Keshan disease is a distinct cardiomyopathy), so HP is the only grounding available - and, with the direction-aware exporter, the correct one.
Sequelae: Thyroidal Oxidative Stress from Selenoprotein Insufficiency
Show evidence (1 reference)
PMID:35789269 SUPPORT Human Clinical
"The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
Prospective cohort evidence grounding selenium deficiency as a modifiable risk state associated with onset of thyroid autoimmunity.
🧬

Genetic Associations

7
HLA-DR3 (Risk Factor)
Show evidence (1 reference)
PMID:26235382 SUPPORT Human Clinical
"AITD susceptibility genes can be categorized as either thyroid specific (Tg, TSHR) or immune-modulating (FOXP3, CD25, CD40, CTLA-4, HLA), with HLA-DR3 carrying the highest risk."
HLA-DR3 is identified as a major immune-genetic risk factor in autoimmune thyroid disease, including HT.
HLA-DR4 (Risk Factor)
Show evidence (1 reference)
PMID:29174716 SUPPORT Human Clinical
"'DRB1*04+GG' (PL: p=0.003; HT: p=0.008)"
HLA-DRB1*04 contributes to susceptibility in combination with CTLA4 risk genotype in HT cohorts.
CTLA4 (Risk Factor)
Gene: CTLA4 hgnc:2505 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CTLA4 (hgnc:2505). hgnc:2505 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PMID:41498152 SUPPORT Human Clinical
"CTLA4 polymorphisms were associated with an elevated risk of a thyroid disease and poorer glycemic control;"
CTLA4 polymorphisms are associated with increased autoimmune thyroid disease risk.
PTPN22 (Risk Factor)
Gene: PTPN22 hgnc:9652 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PTPN22 (hgnc:9652). hgnc:9652 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PMID:33103521 SUPPORT Human Clinical
"This meta-analysis showed that the PTPN22 R620W polymorphism is associated with the risk of GD and HT in the overall study population."
Meta-analysis supports PTPN22 as a susceptibility locus for Hashimoto's thyroiditis.
LAG3 (Risk Factor)
Gene: LAG3 hgnc:6476 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is LAG3 (hgnc:6476). hgnc:6476 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:38982041 SUPPORT Human Clinical
"rs781745126-T reduces mRNA and surface expression of the inhibitory immune checkpoint LAG-3 co-receptor on activated lymphocyte subsets and halves LAG-3 levels in plasma among heterozygotes."
A rare LAG3 5'-UTR start-codon variant lowers the inhibitory checkpoint LAG-3, unleashing autoreactive lymphocytes and conferring the largest single-variant AITD risk (OR 3.42).
CCDC77 (Protective)
Gene: CCDC77 hgnc:28203 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CCDC77 (hgnc:28203). hgnc:28203 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (2 references)
PMID:42283571 SUPPORT Human Clinical
"MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
Mendelian randomization using eQTL/GWAS data identifies CCDC77 as genetically associated with HT through IL-6.
PMID:42283571 SUPPORT Model Organism
"knockdown of CCDC77 exacerbated thyroid damage, increased serum anti-thyroperoxidase antibody (TPOAb), anti-thyroglobulin antibody (TGAb), and IL-6 levels, while reduced free triiodothyronine (FT3) and free thyroxine (FT4)."
NOD mouse knockdown demonstrates that CCDC77 loss exacerbates thyroid autoimmunity, confirming CCDC77 as protective through NF-κB-IL-6 signaling.
SLC45A3 (Risk Factor)
Gene: SLC45A3 hgnc:8642 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SLC45A3 (hgnc:8642). hgnc:8642 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (2 references)
PMID:42283571 SUPPORT Human Clinical
"MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
Mendelian randomization using eQTL/GWAS data identifies SLC45A3 as genetically associated with HT through IL-6.
PMID:42283571 SUPPORT Model Organism
"SLC45A3 knockdown alleviated thyroiditis, reduced antibody levels, and improved thyroid function."
NOD mouse knockdown shows that SLC45A3 reduction ameliorates thyroid autoimmunity, confirming SLC45A3 as a risk factor via NF-κB-IL-6 axis.
💊

Medical Actions

4
Levothyroxine
Thyroid hormone replacement therapy, the mainstay of treatment. It corrects the hormone deficiency by bypassing the destroyed gland but does not address the upstream autoimmunity or inflammation.
Mechanism Target:
BYPASSES Thyroid Hormone Deficiency — Exogenous levothyroxine restores circulating T4/T3 and normalizes TSH, bypassing the hormone-synthesis capacity lost to glandular destruction.
Show evidence (1 reference)
PMID:35235282 SUPPORT Human Clinical
"Management includes thyroid hormone replacement, ideally levothyroxine."
Levothyroxine replaces the deficient thyroid hormone output.
Show evidence (1 reference)
PMID:35235282 SUPPORT Human Clinical
"Management includes thyroid hormone replacement, ideally levothyroxine."
Levothyroxine is standard hormone replacement therapy in hypothyroidism due to HT.
Selenium Supplementation
Adjunctive selenium can lower thyroid autoantibody titers, but a 2024 multicenter double-blind RCT found no quality-of-life benefit over placebo in LT4-treated autoimmune thyroiditis, illustrating a biomarker-outcome dissociation.
Mechanism Target:
MODULATES Autoimmune Thyroid Destruction — Selenium lowers TPO antibody titers, a serologic readout of the autoimmune process, without clearly altering clinical outcome.
Show evidence (1 reference)
PMID:38243784 SUPPORT Human Clinical
"In people with HT without THRT, selenium was effective and safe in lowering TSH, TPOAb, and MDA levels."
Selenium modulates the autoimmune biomarker profile (TPOAb) in HT.
Show evidence (2 references)
PMID:38243784 SUPPORT Human Clinical
"In people with HT without THRT, selenium was effective and safe in lowering TSH, TPOAb, and MDA levels."
Meta-analysis supports selenium as a potential adjunct in selected HT patients.
PMID:38215286 SUPPORT Human Clinical
"no difference in any of the ThyPRO-39 scales was found between the selenium group and the placebo group after 12 months of intervention"
A 412-patient double-blind RCT found selenium gave no quality-of-life benefit over placebo despite biochemical antibody effects, tempering enthusiasm for routine use.
Vitamin D Supplementation
Cholecalciferol supplementation in vitamin D-deficient HT patients can lower thyroid autoantibody titers; evidence is preliminary and further randomized trials are needed.
Mechanism Target:
MODULATES Autoimmune Thyroid Destruction — Vitamin D's immunomodulatory action is associated with reduced thyroid autoantibody titers in deficient patients.
Show evidence (1 reference)
PMID:38542128 SUPPORT Human Clinical
"after the supplementation with cholecalciferol in patients with HT and vitamin D deficiency, thyroid autoantibody titers decreased significantly."
Cholecalciferol supplementation reduces thyroid autoantibody titers in vitamin D-deficient HT patients.
Show evidence (1 reference)
PMID:38542128 SUPPORT Human Clinical
"after the supplementation with cholecalciferol in patients with HT and vitamin D deficiency, thyroid autoantibody titers decreased significantly."
Supports vitamin D repletion as an adjunct that lowers autoantibody titers in deficient HT patients.
Monitoring
Regular TSH monitoring to adjust replacement dose.
Show evidence (1 reference)
PMID:35235282 SUPPORT Human Clinical
"Thyroid hormone should be titrated based on goal TSH values, symptoms, and potential treatment adverse effects."
Ongoing TSH-based monitoring is required to titrate thyroid hormone replacement.
🌍

Environmental Factors

4
Iodine Excess
excess iodine exposure ECTO:9000084 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is increased excess iodine exposure, annotated with exposure to iodine (ECTO:9000084). ECTO:9000084 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Can trigger or worsen disease
Show evidence (1 reference)
PMID:28290237 SUPPORT Human Clinical
"Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin (Tg) is more immunogenic."
Excess iodine exposure is associated with autoimmune thyroiditis in HT-focused nutritional risk literature.
Mechanism Target:
TRIGGERS Thyroglobulin Hyperiodination and Neoantigen Formation — Excess iodine directly raises the iodination of thyroglobulin, and the more heavily iodinated protein is the more immunogenic one. That is why iodine supplementation programmes are followed by a rise in autoimmune thyroiditis. The immunogenic hyperiodinated-Tg state is now the explicit intermediate node feeding the loss of tolerance.
Show evidence (1 reference)
PMID:28290237 SUPPORT Human Clinical
"Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin (Tg) is more immunogenic."
States that chronic excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin is more immunogenic, naming the intervening step.
Low Dietary Selenium Intake
low dietary selenium exposure ECTO:9000950 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is decreased low dietary selenium exposure, annotated with exposure to selenium (ECTO:9000950). ECTO:9000950 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
May increase risk
Show evidence (1 reference)
PMID:35789269 SUPPORT Human Clinical
"The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
Prospective cohort data support selenium deficiency as a modifiable risk factor for Hashimoto's thyroiditis.
Mechanism Target:
TRIGGERS Selenium Deficiency — Low habitual selenium intake is the exposure that produces the systemic "Selenium Deficiency" state, which in turn drives thyroidal oxidative stress.
Show evidence (1 reference)
PMID:35789269 SUPPORT Human Clinical
"The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
Links low selenium supply (the dietary exposure) to the selenium-deficiency state and increased thyroid autoantibody seroconversion.
Hepatitis C Virus Infection
viral exposure ECTO:3000001 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is viral exposure, annotated with exposure to virus (ECTO:3000001). ECTO:3000001 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
HCV is the specific virus with human evidence; other candidate viruses are unverified here (see the pathophysiology node notes).
Show evidence (1 reference)
PMID:32107168 SUPPORT Human Clinical
"Many studies showed that HCV is associated with thyroid autoimmunity and hypothyroidism, in patients with chronic HCV hepatitis (CHC); a significant link has been shown also between HCV-related mixed cryoglobulinemia and risk for GD."
Chronic hepatitis C virus infection is associated with thyroid autoimmunity and hypothyroidism.
Mechanism Target:
PREDISPOSES Hepatitis C Virus-Associated Thyroid Immune Activation — Chronic hepatitis C virus (HCV) infection directly drives the antiviral immune activation captured by the intermediate node. Molecular mimicry and bystander activation are the usual proposals for how that then breaks tolerance, but the cited evidence is an association with chronic hepatitis C rather than a demonstration of either, and interferon treatment of that infection is itself thyrotoxic, which confounds the association.
Show evidence (1 reference)
PMID:32107168 SUPPORT Human Clinical
"Many studies showed that HCV is associated with thyroid autoimmunity and hypothyroidism, in patients with chronic HCV hepatitis (CHC); a significant link has been shown also between HCV-related mixed cryoglobulinemia and risk for GD."
Reports that hepatitis C virus is associated with thyroid autoimmunity and hypothyroidism in patients with chronic infection, an association rather than a mechanism.
Low Vitamin D Intake and Cutaneous Synthesis
low vitamin D exposure ECTO:9000133 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is decreased low vitamin D exposure, annotated with exposure to vitamin D (ECTO:9000133). ECTO:9000133 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Low vitamin D status is consistently associated with HT; vitamin D has an immunomodulatory role promoting immune tolerance, and its deficiency is a candidate modifiable risk factor.
Show evidence (1 reference)
PMID:38542128 SUPPORT Human Clinical
"There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people."
A 2024 review confirms vitamin D levels are significantly lower in HT patients, supporting deficiency as an associated environmental risk factor.
Mechanism Target:
PREDISPOSES Vitamin D Deficiency — Inadequate dietary vitamin D and reduced cutaneous synthesis are the exposure that produces the systemic vitamin D-deficiency state (the grounded "Vitamin D Deficiency" state, MONDO:0100471). This is the weakest of the risk factors and the most exposed to reverse causation: the cited finding is that levels are lower in people who already have the disease, which cross-sectional data cannot separate from chronic illness lowering vitamin D. Recorded as PREDISPOSES rather than TRIGGERS for that reason, matching how the HCV edge is qualified.
Show evidence (1 reference)
PMID:38542128 SUPPORT INDIRECT Human Clinical
"There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people."
INDIRECT because the snippet supports only half of what this edge asserts: it establishes that the deficiency state is associated with HT, but says nothing about dietary intake or cutaneous synthesis as the route to that state. It is also a cross-sectional comparison, so it does not establish direction.
🔬

Biochemical Markers

4
TSH (Elevated)
Context: Primary hypothyroidism
Pathograph Readouts
Readout Of Thyroid Hormone Deficiency Positive Diagnostic
Compensatory TSH elevation is the biochemical hallmark that reports the thyroid hormone synthesis deficit in primary hypothyroidism.
Show evidence (1 reference)
PMID:35235282 SUPPORT Human Clinical
"Overt hypothyroidism occurs when a patient has an elevated TSH level and a low free T4 level with symptoms of hypothyroidism."
Elevated TSH is a core biochemical feature of overt hypothyroidism in Hashimoto's disease.
Free T4 (Decreased)
Context: Overt hypothyroidism
Pathograph Readouts
Readout Of Thyroid Hormone Deficiency Negative Diagnostic
Low free T4 directly measures the reduced thyroid hormone output; lower values track with more severe hormone deficiency.
Show evidence (1 reference)
PMID:35235282 SUPPORT Human Clinical
"Overt hypothyroidism occurs when a patient has an elevated TSH level and a low free T4 level with symptoms of hypothyroidism."
Low free T4 defines overt hypothyroidism and supports this biochemical pattern.
Anti-TPO Antibodies (Elevated)
Context: Diagnostic marker
Pathograph Readouts
Readout Of Autoimmune Thyroid Destruction Present Absent Diagnostic
Anti-TPO positivity reports the ongoing autoimmune attack on thyroid peroxidase and is the principal serologic marker of the destructive process.
Show evidence (1 reference)
PMID:38731922 SUPPORT Human Clinical
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Supports anti-TPO positivity as a characteristic diagnostic marker in HT.
Anti-Thyroglobulin Antibodies (Elevated)
Context: Present in majority of patients
Pathograph Readouts
Readout Of Autoimmune Thyroid Destruction Present Absent Diagnostic
Anti-thyroglobulin positivity reflects humoral autoimmunity against thyroglobulin accompanying follicular destruction.
Show evidence (1 reference)
PMID:38731922 SUPPORT Human Clinical
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Supports elevated anti-thyroglobulin antibodies in HT.
📊

Related Datasets

1
GTEx v8 Thyroid tissue RNA-seq in Hashimoto case-control analysis gtex:GTEx_v8_Thyroid
Bulk RNA-seq analysis of thyroid tissue from GTEx v8 used in a case-control comparison of histopathologically confirmed Hashimoto's thyroiditis and matched controls.
Homo sapiens BULK RNA SEQ n=104
thyroid gland UBERON:0002046 Uberon multi-species anatomy ontology (UBERON) Relation: this dataset samples this sample type This dataset samples thyroid gland (UBERON:0002046). UBERON:0002046 is a sample type from the Uberon multi-species anatomy ontology.
Conditions: Histopathologically confirmed Hashimoto's thyroiditis tissue Matched non-Hashimoto thyroid tissue controls
PMID:33085325
Show evidence (1 reference)
DOI:10.48188/so.6.9 SUPPORT Human Clinical
"As part of a case–control design, we analyzed thyroid tissue RNA sequencing libraries from the Genotype-Tissue Expression Project (v8 release)."
The dataset entry captures the GTEx v8 thyroid RNA-seq source used to compare Hashimoto and control thyroid tissue transcriptomes.
{ }

Source YAML

click to show 
name: Hashimoto's Thyroiditis
creation_date: '2025-12-18T17:01:35Z'
description: >-
  Hashimoto's thyroiditis is a chronic autoimmune disease and the leading cause
  of primary hypothyroidism, in which loss of immune tolerance to thyroid
  antigens (thyroid peroxidase and thyroglobulin) drives lymphocytic
  infiltration and progressive destruction of thyroid follicular cells. CD4 and
  CD8 T cells together with anti-TPO and anti-thyroglobulin autoantibodies
  deplete the gland, producing thyroid hormone deficiency that manifests as
  fatigue, weight gain, cold intolerance, and goiter. Susceptibility is
  conferred by HLA and other immune-regulatory loci interacting with
  environmental triggers such as iodine excess and viral infection, and
  levothyroxine replacement reverses the hypothyroid syndrome.
category: Complex
parents:
- Autoimmune Disease
- Endocrine Disease
disease_term:
  preferred_term: Hashimoto thyroiditis
  term:
    id: MONDO:0007699
    label: Hashimoto thyroiditis
mechanistic_hypotheses:
- hypothesis_group_id: canonical_autoimmune_thyrocyte_destruction_model
  hypothesis_label: Canonical Autoimmune Thyrocyte Destruction Model
  status: CANONICAL
  description: >-
    Hashimoto's thyroiditis is a chronic autoimmune disease in which loss of immune tolerance to thyroid
    antigens — primarily thyroid peroxidase (TPO) and thyroglobulin (Tg) — drives lymphocytic
    infiltration of the thyroid gland, formation of intrathyroidal tertiary lymphoid structures, and
    progressive thyrocyte destruction. CD4 Th1 and Th17 cells, CD8 cytotoxic T cells, and autoantibody-
    mediated effects (anti-TPO, anti-Tg) act together to deplete follicular cells, producing primary
    hypothyroidism. Susceptibility is conferred by HLA-DR3/DR5, CTLA4, PTPN22, and other immune-
    regulation loci, with environmental triggers including iodine excess, viral infection, and selenium
    deficiency. Levothyroxine replacement reverses the hypothyroid syndrome by bypassing the destroyed
    gland, supporting glandular failure as the proximate clinical lesion in this canonical model.
  notes: >-
    Retained as CANONICAL. The 2026 openscientist
    hypothesis-search report
    (kb/hypotheses/Hashimotos_Thyroiditis/canonical_autoimmune_thyrocyte_destruction_model)
    confirms 12 of 13 mechanistic claims as established. Core
    effector mechanisms — Fas/FasL-mediated thyrocyte apoptosis
    (sensitized by IFN-γ + IL-1β, independent of perforin/granzyme),
    intrathyroidal tertiary lymphoid structures functioning as
    germinal centers with RAG1/RAG2 in situ receptor revision, and
    coordinated CD4 Th1/Th17 + CD8 + autoantibody (anti-TPO in
    >90%) responses — are validated by histopathology, single-cell
    transcriptomics, and immune-checkpoint-inhibitor-induced
    thyroiditis as a natural experiment. JAK inhibition has
    provided proof-of-concept reversal. Six refinements: (1) Th17/Treg
    imbalance is now established as an upstream initiator
    preceding Th1-mediated destruction, not captured by the seed
    description; (2) IgG4-related thyroiditis (~27%) and
    seronegative HT (~12%) are clinically significant subtypes the
    model does not address; (3) GWAS identifies 418 independent
    signals (vs ~5 canonical loci) explaining only ~5.4% of
    variance, indicating extensive polygenicity; (4) the gut-
    thyroid axis (molecular mimicry, SCFA depletion) provides a
    mechanistic bridge from environmental triggers to immune
    dysregulation; (5) thyrocyte HLA class II expression (Bottazzo
    hypothesis) and NETosis are increasingly implicated;
    (6) sex-specific intrathyroidal B-cell homing via CXCL13-CXCR5
    helps explain the female predominance. The initial
    tolerance-breaking event remains unknown and no disease-
    modifying RCT has yet been completed.
  evidence:
  - reference: PMID:38731922
    reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
    explanation: >
      Canonical mechanism reference used as the seed for the hypothesis-search
      deep-research run. It supports the autoantibody plus lymphocytic-infiltration
      core of the model, but not the full CD4 Th1/Th17, CD8,
      tertiary-lymphoid-structure, or genetic-susceptibility claims in the
      hypothesis description.
pathophysiology:
- name: Thyroglobulin Hyperiodination and Neoantigen Formation
  description: >-
    Excess iodide drives heavier iodination of thyroglobulin during hormone
    synthesis, and the more heavily iodinated protein carries altered epitopes
    that are more immunogenic than lightly iodinated Tg. This iodine-dependent
    neoantigen state is the proximate biochemical step through which chronic
    iodine excess presents modified self-antigen to the immune system, and is the
    intermediate node inserted between the iodine-excess exposure and the loss of
    tolerance.
  role: trigger
  biological_scale: MOLECULAR
  cell_types:
  - preferred_term: Thyroid Follicular Cell
    term:
      id: CL:0002258
      label: thyroid follicular cell
  biological_processes:
  - preferred_term: Thyroglobulin iodination
    term:
      id: GO:0006590
      label: thyroid hormone generation
    # The claim here is qualitative - thyroglobulin carries abnormal, more
    # immunogenic iodination - not that hormone generation runs above its normal
    # level. INCREASED would also contradict the DECREASED modifier this same GO
    # term carries downstream on the Thyroid Hormone Deficiency node.
    modifier: ABNORMAL
  evidence:
  - reference: PMID:28290237
    reference_title: "Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin (Tg) is more immunogenic."
    explanation: >-
      Names highly iodinated thyroglobulin as the more immunogenic species,
      identifying the intermediate biochemical state linking iodine excess to
      the autoimmune response.
  downstream:
  - target: Loss of Immune Tolerance to Thyroid Antigens
    causal_link_type: DIRECT
    description: >-
      Presentation of the more immunogenic hyperiodinated thyroglobulin promotes
      autoreactive recognition of thyroid self-antigen, contributing to the
      breakdown of tolerance.
- name: Thyroidal Oxidative Stress from Selenoprotein Insufficiency
  description: >-
    Thyroid hormone synthesis generates hydrogen peroxide at the apical thyrocyte
    surface, which selenoprotein glutathione peroxidases normally detoxify. When
    selenium supply is low these selenoenzymes are limiting, so peroxide
    accumulates and oxidatively injures thyroid follicular cells. This oxidative
    thyrocyte injury and antigen release is the mechanism node downstream of the
    "Selenium Deficiency" state and upstream of the loss of tolerance.
  role: trigger
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: Thyroid Follicular Cell
    term:
      id: CL:0002258
      label: thyroid follicular cell
  biological_processes:
  - preferred_term: Peroxide detoxification by glutathione peroxidase
    term:
      id: GO:0042744
      label: hydrogen peroxide catabolic process
    modifier: DECREASED
  - preferred_term: Response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  chemical_entities:
  - preferred_term: hydrogen peroxide
    term:
      id: CHEBI:16240
      label: hydrogen peroxide
    modifier: INCREASED
  evidence:
  - reference: PMID:28290237
    reference_title: "Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the glutathione peroxidases protect the thyroid by removing excessive hydrogen peroxide produced for Tg iodination"
    explanation: >-
      Identifies selenoprotein glutathione peroxidases as the thyroid's defense
      against the hydrogen peroxide of hormone synthesis, so their insufficiency
      in selenium deficiency leaves the gland exposed to oxidative injury.
  - reference: PMID:35789269
    reference_title: "Increased Incidence of Hashimoto Thyroiditis in Selenium Deficiency: A Prospective 6-Year Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
    explanation: >-
      Prospective cohort evidence that low selenium status raises the incidence
      of thyroid autoantibody seroconversion, linking this oxidative-stress state
      to onset of autoimmunity.
  downstream:
  - target: Loss of Immune Tolerance to Thyroid Antigens
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Peroxide-mediated thyrocyte oxidative injury and release of sequestered thyroid antigen
    description: >-
      Oxidative thyrocyte injury releases and modifies sequestered thyroid
      antigens, promoting autoreactive priming and loss of tolerance.
- name: Impaired Vitamin D-Dependent Immune Tolerance
  description: >-
    Vitamin D signaling supports tolerogenic dendritic cells and regulatory
    T-cell function, an immunomodulatory brake that favors self-tolerance. Low
    vitamin D status weakens this brake and is proposed to permit escape from
    immune regulation. The direction of this association is unsettled: the cited
    cross-sectional finding is that levels are lower in people who already have
    the disease, and part of the same nutritional-risk literature attributes the
    low levels to the autoimmune process itself (including vitamin D receptor
    dysfunction) rather than the reverse.
  role: trigger
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: Immune tolerance induction
    term:
      id: GO:0002507
      label: tolerance induction
    modifier: DECREASED
  - preferred_term: Regulation of immune response
    term:
      id: GO:0050776
      label: regulation of immune response
    modifier: DECREASED
  evidence:
  - reference: PMID:38542128
    reference_title: "Autoimmune Thyroiditis and Vitamin D."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Vitamin D carries out an immunomodulatory role that appears to promote immune tolerance."
    explanation: >-
      States vitamin D's immunomodulatory, tolerance-promoting role, the basis
      for treating its deficiency as a state of weakened immune regulation.
  - reference: PMID:38542128
    reference_title: "Autoimmune Thyroiditis and Vitamin D."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hashimoto's thyroiditis (HT) is marked by self-tissue destruction as a consequence of an alteration in the adaptive immune response that entails the evasion of immune regulation."
    explanation: >-
      Frames HT as evasion of immune regulation, the tolerance failure that
      impaired vitamin D-dependent immunomodulation is proposed to promote.
  notes: >-
    Direction of effect is uncertain (reverse causation): low vitamin D in HT
    patients is cross-sectional, and part of the nutritional-risk literature
    (PMID:28290237) argues low vitamin D is more likely a result of the
    autoimmune process, including vitamin D receptor dysfunction.
  downstream:
  - target: Loss of Immune Tolerance to Thyroid Antigens
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Weakened vitamin D-dependent immunoregulation is proposed to lower the
      threshold for loss of tolerance to thyroid antigens, though the causal
      direction is not established.
- name: Hepatitis C Virus-Associated Thyroid Immune Activation
  description: >-
    The specific virus with human evidence here is hepatitis C virus (HCV;
    chronic HCV infection, MONDO:0005354), which is associated with thyroid
    autoimmunity and hypothyroidism. Molecular mimicry between viral and thyroid
    antigens and bystander activation of autoreactive lymphocytes are the usual
    mechanistic proposals, but the cited evidence is an epidemiological
    association, and interferon-based antiviral therapy for HCV is itself
    thyrotoxic, which confounds it. This HCV-associated immune-activation state is
    the intermediate node between the HCV-infection exposure and the loss of
    tolerance.
  role: trigger
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: Defense response to virus
    term:
      id: GO:0051607
      label: defense response to virus
  evidence:
  - reference: PMID:32107168
    reference_title: "Graves' disease: Epidemiology, genetic and environmental risk factors and viruses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Many studies showed that HCV is associated with thyroid autoimmunity and hypothyroidism, in patients with chronic HCV hepatitis (CHC); a significant link has been shown also between HCV-related mixed cryoglobulinemia and risk for GD."
    explanation: >-
      Reports the epidemiological association of chronic HCV infection with
      thyroid autoimmunity and hypothyroidism, the observation behind this
      HCV-associated immune-activation state.
  notes: >-
    The evidence here is specific to hepatitis C virus. Other viruses (EBV,
    HTLV-1, parvovirus B19, enteroviruses, and SARS-CoV-2) have been proposed as
    thyroid-autoimmunity triggers but are not substantiated in the cited source
    and so are not asserted as nodes. IFN-alpha therapy for chronic HCV is itself
    associated with thyroid dysfunction, confounding the HCV-autoimmunity
    association.
  downstream:
  - target: Loss of Immune Tolerance to Thyroid Antigens
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Proposed molecular mimicry between viral and thyroid antigens and bystander lymphocyte activation
    description: >-
      Antiviral immune activation is proposed to break tolerance to thyroid
      antigens via molecular mimicry or bystander activation, a mechanism not
      established by the cited association.
- name: Loss of Immune Tolerance to Thyroid Antigens
  description: >
    Susceptibility variants in T-cell regulatory and immune-checkpoint genes
    (HLA class II, CTLA4, PTPN22, LAG3) act together with environmental triggers
    (iodine excess, selenium/vitamin D status, viral infection) to break
    self-tolerance to thyroid peroxidase and thyroglobulin, the initiating lesion
    that licenses autoreactive T- and B-cell responses against the thyroid. A
    rare LAG3 start-codon variant that lowers the inhibitory checkpoint LAG-3
    exemplifies how impaired T-cell down-regulation predisposes to autoimmune
    thyroid disease.
  role: trigger
  genes:
  - preferred_term: CTLA4
    term:
      id: hgnc:2505
      label: CTLA4
  - preferred_term: PTPN22
    term:
      id: hgnc:9652
      label: PTPN22
  - preferred_term: LAG3
    term:
      id: hgnc:6476
      label: LAG3
  evidence:
  - reference: PMID:38982041
    reference_title: "Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Multiomics analysis yields 235 candidate genes outside the MHC-region and the findings highlight the importance of genes involved in T-cell regulation."
    explanation: A large AITD GWAS meta-analysis localizes susceptibility to T-cell regulatory genes, supporting loss of T-cell tolerance as the initiating mechanism.
  downstream:
  - target: Thyrocyte Antigen Presentation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Autoreactive T helper cell priming against TPO/Tg
    description: >
      Breakdown of tolerance permits autoreactive T cells and an interferon-rich
      milieu that drives thyroid follicular cells to present antigen.
  - target: Lymphocytic Infiltration
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Autoreactive lymphocyte activation and thyroid homing
    description: >
      Loss of tolerance licenses autoreactive T and B lymphocytes that traffic
      into and accumulate within the thyroid gland.
- name: Thyrocyte Antigen Presentation
  description: >
    Under interferon-gamma and TNF-alpha exposure, thyroid follicular cells
    aberrantly upregulate MHC class II together with the invariant chain CD74 and
    its ligand MIF, becoming non-professional antigen-presenting cells. This
    amplifies local antigen presentation and ligand-receptor cross-talk with
    infiltrating immune cells, sustaining and propagating the intrathyroidal
    autoimmune response.
  role: amplifier
  cell_types:
  - preferred_term: Thyroid Follicular Cell
    term:
      id: CL:0002258
      label: thyroid follicular cell
  biological_processes:
  - preferred_term: Antigen presentation via MHC class II
    term:
      id: GO:0002495
      label: antigen processing and presentation of peptide antigen via MHC class II
    modifier: INCREASED
  evidence:
  - reference: PMID:39003267
    reference_title: "Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identify damaged antigen-presenting TFCs with upregulated CD74 and MIF expression in thyroid samples from AITD patients."
    explanation: Spatial transcriptomics shows thyroid follicular cells act as antigen-presenting cells via CD74/MIF upregulation, driving local autoimmunity.
    images:
    - Hashimotos_Thyroiditis-deep-research-falcon_artifacts/image-1.png
  downstream:
  - target: Lymphocytic Infiltration
    causal_link_type: DIRECT
    description: >
      Thyrocyte antigen presentation and chemokine expression recruit and
      activate infiltrating lymphocytes within the gland.
- name: Autoimmune Thyroid Destruction
  description: >
    T cell-mediated and antibody-mediated destruction of thyroid follicular
    cells leads to progressive loss of thyroid function. Anti-thyroid
    peroxidase (anti-TPO) and anti-thyroglobulin antibodies are characteristic.
  cell_types:
  - preferred_term: Thyroid Epithelial Cell
    term:
      id: CL:0002257
      label: epithelial cell of thyroid gland
  - preferred_term: T Helper Cell
    term:
      id: CL:0000492
      label: CD4-positive helper T cell
  biological_processes:
  - preferred_term: Autoimmune Response
    term:
      id: GO:0002460
      label: adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
  evidence:
  - reference: PMID:39003267
    reference_title: "Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identify damaged antigen-presenting TFCs with upregulated CD74 and MIF expression in thyroid samples from AITD patients."
    explanation: Spatial transcriptomics demonstrates that thyroid follicular cells actively participate in autoimmune destruction by presenting antigens via CD74/MIF upregulation.
  - reference: PMID:38731922
    reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
    explanation: Confirms the characteristic antibody profile and lymphocytic infiltration pattern in Hashimoto's thyroiditis.
  - reference: PMID:40535343
    reference_title: "Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Through this review, we aim to establish mechanistic connections between ICI pharmacodynamics and thyroid tissue immunopathology."
    explanation: ICI-induced thyroiditis provides a mechanistic model that mirrors the autoimmune destruction seen in spontaneous Hashimoto's thyroiditis.
  downstream:
  - target: Thyroid Hormone Deficiency
    causal_link_type: DIRECT
    description: >
      Progressive cytotoxic and antibody-mediated loss of hormone-producing
      follicular cells depletes the gland's capacity to synthesize T3 and T4,
      producing thyroid hormone deficiency.
    evidence:
    - reference: PMID:38731922
      reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Due to the progressive destruction of cells, AITD can lead to subclinical or overt hypothyroidism."
      explanation: Directly links progressive follicular-cell destruction to the resulting hypothyroid hormone deficit.
  - target: Hashitoxicosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Release of preformed thyroid hormone from destroyed follicles
    description: >
      Early inflammatory destruction of follicles can release preformed stored
      hormone, producing a transient thyrotoxic (hashitoxicosis) phase before
      glandular reserve is exhausted and hypothyroidism supervenes.
    evidence:
    - reference: PMID:24434360
      reference_title: "Hashimoto thyroiditis: clinical and diagnostic criteria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "at presentation patients can be euthyroid or even hyperthyroid"
      explanation: Supports a transient hyperthyroid presentation arising from destructive release of stored hormone.
- name: Lymphocytic Infiltration
  description: >
    Dense lymphocytic infiltration of the thyroid gland with germinal
    center formation. CD4+ T cells, CD8+ T cells, and B cells accumulate
    in the thyroid parenchyma.
  biological_processes:
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: Adaptive immune response
    term:
      id: GO:0002250
      label: adaptive immune response
  cell_types:
  - preferred_term: CD4-positive helper T cell
    term:
      id: CL:0000492
      label: CD4-positive helper T cell
  - preferred_term: CD8-positive, alpha-beta T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  - preferred_term: B Cell
    term:
      id: CL:0000236
      label: B cell
  evidence:
  - reference: PMID:38731922
    reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
    explanation: Lymphocytic infiltration is a defining histological feature of Hashimoto's thyroiditis.
  - reference: PMID:39003267
    reference_title: "Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we use spatial transcriptomics to explore the molecular architecture, heterogeneity and location of different cells present in the thyroid tissue, including thyroid follicular cells (TFCs), stromal cells such as fibroblasts, endothelial cells, and thyroid infiltrating lymphocytes."
    explanation: Spatial analysis confirms the presence and organization of infiltrating lymphocytes in the thyroid microenvironment.
  downstream:
  - target: Autoimmune Thyroid Destruction
    causal_link_type: DIRECT
    description: >
      Infiltrating cytotoxic T cells, autoantibody-producing B/plasma cells, and
      inflammatory macrophages execute follicular-cell killing.
    evidence:
    - reference: PMID:38731922
      reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
      explanation: Links the lymphocytic infiltrate and thyroid autoantibodies to the destructive autoimmune process.
  - target: Goiter
    causal_link_type: DIRECT
    description: >
      Dense inflammatory infiltration and lymphoid-follicle formation enlarge the
      gland, producing the characteristic diffuse goiter.
- name: NF-κB-IL-6 Signaling Pathway Activation
  description: >
    Genetic regulation of NF-κB and IL-6 signaling modulates the autoimmune
    response in Hashimoto's thyroiditis. CCDC77 and SLC45A3 are novel genetic
    modifiers that regulate NF-κB pathway activation and IL-6 production. CCDC77
    acts as a protective regulator (knockdown exacerbates thyroid damage),
    while SLC45A3 acts as a disease-promoting factor (knockdown alleviates thyroiditis).
    The NF-κB-IL-6 axis modulates immune cell activation and thyroid-targeted autoimmunity.
  biological_processes:
  - preferred_term: NF-κB signaling pathway
    term:
      id: GO:0007249
      label: canonical NF-kappaB signal transduction
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  evidence:
  - reference: PMID:42283571
    reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
    explanation: Two-sample Mendelian randomization using human eQTL/GWAS data identified CCDC77 and SLC45A3 as IL-6-linked genes associated with Hashimoto's thyroiditis.
  - reference: PMID:42283571
    reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In vivo experiments showed that knockdown of CCDC77 exacerbated thyroid damage, increased serum anti-thyroperoxidase antibody (TPOAb), anti-thyroglobulin antibody (TGAb), and IL-6 levels, while reduced free triiodothyronine (FT3) and free thyroxine (FT4). Conversely, SLC45A3 knockdown alleviated thyroiditis, reduced antibody levels, and improved thyroid function."
    explanation: In vivo validation in NOD mice demonstrates that CCDC77 and SLC45A3 regulate HT progression through the NF-κB-IL-6 signaling axis; CCDC77 is a protective modulator while SLC45A3 is disease-promoting.
  downstream:
  - target: Lymphocytic Infiltration
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - IL-6-driven Th17 differentiation and immune-cell activation
    description: >
      Genetic modulation of the NF-κB-IL-6 axis tunes immune-cell activation and
      recruitment, amplifying the intrathyroidal lymphocytic infiltrate.
    evidence:
    - reference: PMID:42283571
      reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In vivo experiments showed that knockdown of CCDC77 exacerbated thyroid damage, increased serum anti-thyroperoxidase antibody (TPOAb), anti-thyroglobulin antibody (TGAb), and IL-6 levels, while reduced free triiodothyronine (FT3) and free thyroxine (FT4). Conversely, SLC45A3 knockdown alleviated thyroiditis, reduced antibody levels, and improved thyroid function."
      explanation: NOD-mouse knockdown of NF-κB-IL-6 axis genes changes thyroid damage and antibody levels, linking this signaling node to the autoimmune infiltrate.
- name: Thyroid Hormone Deficiency
  conforms_to: "hypothyroidism_thyroid_hormone_deficiency#Impaired Thyroid Hormone Synthesis"
  description: >
    Progressive destruction of thyroid tissue leads to decreased
    production of T3 and T4, resulting in hypothyroidism with elevated
    TSH through negative feedback.
  biological_processes:
  - preferred_term: Thyroid Hormone Synthesis
    term:
      id: GO:0006590
      label: thyroid hormone generation
    modifier: DECREASED
  evidence:
  - reference: PMID:38731922
    reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Due to the progressive destruction of cells, AITD can lead to subclinical or overt hypothyroidism."
    explanation: Progressive thyroid destruction in Hashimoto's thyroiditis results in hypothyroidism through loss of hormone-producing cells.
  downstream:
  - target: Hypothyroidism
    causal_link_type: DIRECT
    description: >
      Insufficient T3/T4 output with compensatory TSH elevation manifests
      clinically as primary hypothyroidism.
    evidence:
    - reference: PMID:32805423
      reference_title: "Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "developing a primary hypothyroidism"
      explanation: The hormone-synthesis deficit produces clinical primary hypothyroidism.
phenotypes:
- name: Vitamin D Deficiency
  category: Nutritional
  description: >-
    Decreased circulating vitamin D (HP:0100512) modeled here as an upstream,
    modifiable risk state rather than a manifestation of the thyroid disease. As
    a deficiency state it is a convergence point reachable by several routes -
    reduced dietary intake, reduced cutaneous (UVB) synthesis, or impaired
    intestinal absorption (relevant in HT given its comorbidity with autoimmune
    gastritis and celiac disease). Only the intake/synthesis route is currently
    wired in as an evidenced edge. It is consistently observed at lower levels in
    HT patients; the causal direction is uncertain (see notes).
  phenotype_term:
    preferred_term: Vitamin D deficiency
    term:
      id: HP:0100512
      label: Decreased circulating vitamin D concentration
  evidence:
  - reference: PMID:38542128
    reference_title: "Autoimmune Thyroiditis and Vitamin D."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people."
    explanation: >-
      Grounds the vitamin D-deficiency state as a finding associated with HT.
  notes: >-
    HP:0100512 is bound here as an upstream risk state, not a manifestation:
    because this phenotype has a sequelae edge into a pathophysiology node, the
    KGX/HPOA exporters export it as a direction-neutral
    `MONDO:0007699 biolink:associated_with HP:0100512` rather than
    `has_phenotype`. (This supersedes the earlier workaround of binding
    MONDO:0100471 to dodge the has_phenotype inversion; the direction-aware
    exporter makes the HP binding correct.) The association is cross-sectional
    and may be bidirectional; part of the nutritional-risk literature
    (PMID:28290237) attributes low vitamin D to the autoimmune process itself,
    including vitamin D receptor dysfunction.
  sequelae:
  - target: Impaired Vitamin D-Dependent Immune Tolerance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Vitamin D deficiency is proposed to weaken vitamin D-dependent
      immunoregulation; the causal direction is not established.
- name: Selenium Deficiency
  category: Nutritional
  description: >-
    Decreased circulating selenium (HP:0033192) modeled here as an upstream,
    modifiable risk state for HT. As a deficiency state it is a convergence point
    reachable by reduced dietary intake or impaired intestinal absorption
    (relevant in HT given its comorbidity with autoimmune gastritis and celiac
    disease); only the intake route is currently wired in as an evidenced edge.
    Low selenium status raises the incidence of thyroid autoantibody
    seroconversion.
  phenotype_term:
    preferred_term: Selenium deficiency
    term:
      id: HP:0033192
      label: Decreased circulating selenium concentration
  evidence:
  - reference: PMID:35789269
    reference_title: "Increased Incidence of Hashimoto Thyroiditis in Selenium Deficiency: A Prospective 6-Year Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
    explanation: >-
      Prospective cohort evidence grounding selenium deficiency as a modifiable
      risk state associated with onset of thyroid autoimmunity.
  notes: >-
    HP:0033192 is bound here as an upstream risk state, not a manifestation. The
    KGX/HPOA exporters detect that (this phenotype has a sequelae edge into a
    pathophysiology node) and export it as a direction-neutral
    `MONDO:0007699 biolink:associated_with HP:0033192` rather than
    `has_phenotype`, so the export does not invert the cited prospective cohort
    in which low selenium supply *precedes* TPO-Ab seroconversion. MONDO has no
    human selenium-deficiency class (MONDO:1017720 is explicitly
    non-human-animal, MONDO:0000241 Keshan disease is a distinct cardiomyopathy),
    so HP is the only grounding available - and, with the direction-aware
    exporter, the correct one.
  sequelae:
  - target: Thyroidal Oxidative Stress from Selenoprotein Insufficiency
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Loss of selenoprotein glutathione-peroxidase antioxidant capacity
    description: >-
      Selenium deficiency limits selenoprotein glutathione peroxidases, driving
      thyroidal oxidative stress.
- name: Fatigue
  category: Systemic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:35235282
    reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
    explanation: Hashimoto-associated hypothyroidism commonly presents with fatigue.
- name: Weight Gain
  category: Metabolic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Weight Gain
    term:
      id: HP:0004324
      label: Increased body weight
  evidence:
  - reference: PMID:35235282
    reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
    explanation: Weight gain is a common hypothyroid symptom in Hashimoto's thyroiditis.
- name: Constipation
  category: Gastrointestinal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:35235282
    reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
    explanation: Constipation is a recognized symptom in hypothyroid states.
- name: Dry Skin
  category: Dermatological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dry Skin
    term:
      id: HP:0000958
      label: Dry skin
  evidence:
  - reference: PMID:35235282
    reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
    explanation: Dry skin is a common dermatologic manifestation of hypothyroidism.
- name: Cold Intolerance
  category: Systemic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cold Intolerance
    term:
      id: HP:6000855
      label: Cold intolerance
  evidence:
  - reference: PMID:35235282
    reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
    explanation: Cold intolerance is a common symptom of hypothyroidism in Hashimoto's thyroiditis.
- name: Goiter
  category: Endocrine
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Goiter
    term:
      id: HP:0000853
      label: Goiter
  evidence:
  - reference: PMID:38731922
    reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
    explanation: Goiter develops due to lymphocytic infiltration and inflammatory enlargement of the thyroid gland.
- name: Depression
  category: Psychiatric
  notes: >-
    Frequency band deliberately omitted: the only cited source lists depression
    among the "most common presenting symptoms", which conflicts with the
    previously curated OCCASIONAL (5-29%) band and provides no quantitative
    estimate. Per the frequency-evidence guidelines, no band is asserted.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:23744563
    reference_title: "Selenium supplementation for Hashimoto's thyroiditis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common presenting symptoms may include anxiety, negative mood, depression, dry skin, cold intolerance, puffy eyes, muscle cramps and fatigue, deep voice, constipation, slow thinking and poor memory."
    explanation: Depression is reported among common presenting symptoms in Hashimoto's thyroiditis.
- name: "Hypothyroidism"
  category: Endocrine
  description: "Autoimmune destruction of the thyroid gland in Hashimoto thyroiditis produces primary hypothyroidism."
  phenotype_term:
    preferred_term: "Hypothyroidism"
    term:
      id: HP:0000821
      label: "Hypothyroidism"
  evidence:
  - reference: PMID:32805423
    reference_title: "Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "developing a primary hypothyroidism"
    explanation: "This review states Hashimoto thyroiditis develops a primary hypothyroidism."
  sequelae:
  - target: Fatigue
  - target: Weight Gain
  - target: Cold Intolerance
  - target: Dry Skin
  - target: Constipation
  - target: Depression
- name: "Hashitoxicosis"
  category: Endocrine
  description: "A transient hyperthyroid phase (Hashitoxicosis) can occur at presentation of Hashimoto thyroiditis before evolution to hypothyroidism."
  phenotype_term:
    preferred_term: "Hashitoxicosis (transient hyperthyroidism)"
    term:
      id: HP:0000836
      label: "Hyperthyroidism"
  evidence:
  - reference: PMID:24434360
    reference_title: "Hashimoto thyroiditis: clinical and diagnostic criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "at presentation patients can be euthyroid or even hyperthyroid"
    explanation: "This clinical-criteria review notes patients may be hyperthyroid at presentation of Hashimoto thyroiditis."
biochemical:
- name: TSH
  presence: Elevated
  context: Primary hypothyroidism
  evidence:
  - reference: PMID:35235282
    reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overt hypothyroidism occurs when a patient has an elevated TSH level and a low free T4 level with symptoms of hypothyroidism."
    explanation: Elevated TSH is a core biochemical feature of overt hypothyroidism in Hashimoto's disease.
  readouts:
  - target: Thyroid Hormone Deficiency
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Compensatory TSH elevation is the biochemical hallmark that reports the
      thyroid hormone synthesis deficit in primary hypothyroidism.
- name: Free T4
  presence: Decreased
  context: Overt hypothyroidism
  evidence:
  - reference: PMID:35235282
    reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overt hypothyroidism occurs when a patient has an elevated TSH level and a low free T4 level with symptoms of hypothyroidism."
    explanation: Low free T4 defines overt hypothyroidism and supports this biochemical pattern.
  readouts:
  - target: Thyroid Hormone Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Low free T4 directly measures the reduced thyroid hormone output; lower
      values track with more severe hormone deficiency.
- name: Anti-TPO Antibodies
  presence: Elevated
  context: Diagnostic marker
  evidence:
  - reference: PMID:38731922
    reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
    explanation: Supports anti-TPO positivity as a characteristic diagnostic marker in HT.
  readouts:
  - target: Autoimmune Thyroid Destruction
    relationship: READOUT_OF
    direction: PRESENT_ABSENT
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Anti-TPO positivity reports the ongoing autoimmune attack on thyroid
      peroxidase and is the principal serologic marker of the destructive process.
- name: Anti-Thyroglobulin Antibodies
  presence: Elevated
  context: Present in majority of patients
  evidence:
  - reference: PMID:38731922
    reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
    explanation: Supports elevated anti-thyroglobulin antibodies in HT.
  readouts:
  - target: Autoimmune Thyroid Destruction
    relationship: READOUT_OF
    direction: PRESENT_ABSENT
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Anti-thyroglobulin positivity reflects humoral autoimmunity against
      thyroglobulin accompanying follicular destruction.
genetic:
- name: HLA-DR3
  association: Risk Factor
  evidence:
  - reference: PMID:26235382
    reference_title: "Immunogenetics of autoimmune thyroid diseases: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AITD susceptibility genes can be categorized as either thyroid specific (Tg, TSHR) or immune-modulating (FOXP3, CD25, CD40, CTLA-4, HLA), with HLA-DR3 carrying the highest risk."
    explanation: HLA-DR3 is identified as a major immune-genetic risk factor in autoimmune thyroid disease, including HT.
- name: HLA-DR4
  association: Risk Factor
  evidence:
  - reference: PMID:29174716
    reference_title: "Interaction of HLA-DRB1* alleles and CTLA4 (+49 AG) gene polymorphism in Autoimmune Thyroid Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "'DRB1*04+GG' (PL: p=0.003; HT: p=0.008)"
    explanation: HLA-DRB1*04 contributes to susceptibility in combination with CTLA4 risk genotype in HT cohorts.
- name: CTLA4
  association: Risk Factor
  relationship_type: SUSCEPTIBILITY
  gene_term:
    preferred_term: CTLA4
    term:
      id: hgnc:2505
      label: CTLA4
  evidence:
  - reference: PMID:41498152
    reference_title: "CTLA4, PTNP22, and FOXO3A gene variants as genetic biomarkers for co-occurrence of type 1 diabetes and autoimmune thyroid diseases in the Polish population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CTLA4 polymorphisms were associated with an elevated risk of a thyroid disease and poorer glycemic control;"
    explanation: CTLA4 polymorphisms are associated with increased autoimmune thyroid disease risk.
- name: PTPN22
  association: Risk Factor
  relationship_type: SUSCEPTIBILITY
  gene_term:
    preferred_term: PTPN22
    term:
      id: hgnc:9652
      label: PTPN22
  evidence:
  - reference: PMID:33103521
    reference_title: "The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This meta-analysis showed that the PTPN22 R620W polymorphism is associated with the risk of GD and HT in the overall study population."
    explanation: Meta-analysis supports PTPN22 as a susceptibility locus for Hashimoto's thyroiditis.
- name: LAG3
  association: Risk Factor
  gene_term:
    preferred_term: LAG3
    term:
      id: hgnc:6476
      label: LAG3
  evidence:
  - reference: PMID:38982041
    reference_title: "Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "rs781745126-T reduces mRNA and surface expression of the inhibitory immune checkpoint LAG-3 co-receptor on activated lymphocyte subsets and halves LAG-3 levels in plasma among heterozygotes."
    explanation: A rare LAG3 5'-UTR start-codon variant lowers the inhibitory checkpoint LAG-3, unleashing autoreactive lymphocytes and conferring the largest single-variant AITD risk (OR 3.42).
- name: CCDC77
  gene_term:
    preferred_term: CCDC77
    term:
      id: hgnc:28203
      label: CCDC77
  association: Protective
  evidence:
  - reference: PMID:42283571
    reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
    explanation: Mendelian randomization using eQTL/GWAS data identifies CCDC77 as genetically associated with HT through IL-6.
  - reference: PMID:42283571
    reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "knockdown of CCDC77 exacerbated thyroid damage, increased serum anti-thyroperoxidase antibody (TPOAb), anti-thyroglobulin antibody (TGAb), and IL-6 levels, while reduced free triiodothyronine (FT3) and free thyroxine (FT4)."
    explanation: NOD mouse knockdown demonstrates that CCDC77 loss exacerbates thyroid autoimmunity, confirming CCDC77 as protective through NF-κB-IL-6 signaling.
- name: SLC45A3
  gene_term:
    preferred_term: SLC45A3
    term:
      id: hgnc:8642
      label: SLC45A3
  association: Risk Factor
  evidence:
  - reference: PMID:42283571
    reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
    explanation: Mendelian randomization using eQTL/GWAS data identifies SLC45A3 as genetically associated with HT through IL-6.
  - reference: PMID:42283571
    reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "SLC45A3 knockdown alleviated thyroiditis, reduced antibody levels, and improved thyroid function."
    explanation: NOD mouse knockdown shows that SLC45A3 reduction ameliorates thyroid autoimmunity, confirming SLC45A3 as a risk factor via NF-κB-IL-6 axis.
environmental:
- name: Iodine Excess
  exposure_term:
    preferred_term: excess iodine exposure
    modifier: INCREASED
    term:
      id: ECTO:9000084
      label: exposure to iodine
  influences_mechanisms:
  - target: Thyroglobulin Hyperiodination and Neoantigen Formation
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Excess iodine directly raises the iodination of thyroglobulin, and the
      more heavily iodinated protein is the more immunogenic one. That is why
      iodine supplementation programmes are followed by a rise in autoimmune
      thyroiditis. The immunogenic hyperiodinated-Tg state is now the explicit
      intermediate node feeding the loss of tolerance.
    evidence:
    - reference: PMID:28290237
      reference_title: "Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin (Tg) is more immunogenic."
      explanation: >-
        States that chronic excess iodine intake induces autoimmune
        thyroiditis, partly because highly iodinated thyroglobulin is more
        immunogenic, naming the intervening step.
  notes: Can trigger or worsen disease
  evidence:
  - reference: PMID:28290237
    reference_title: "Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin (Tg) is more immunogenic."
    explanation: Excess iodine exposure is associated with autoimmune thyroiditis in HT-focused nutritional risk literature.
- name: Low Dietary Selenium Intake
  exposure_term:
    preferred_term: low dietary selenium exposure
    modifier: DECREASED
    term:
      id: ECTO:9000950
      label: exposure to selenium
  influences_mechanisms:
  - target: Selenium Deficiency
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Low habitual selenium intake is the exposure that produces the systemic
      "Selenium Deficiency" state, which in turn drives thyroidal oxidative
      stress.
    evidence:
    - reference: PMID:35789269
      reference_title: "Increased Incidence of Hashimoto Thyroiditis in Selenium Deficiency: A Prospective 6-Year Cohort Study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
      explanation: >-
        Links low selenium supply (the dietary exposure) to the
        selenium-deficiency state and increased thyroid autoantibody
        seroconversion.
  notes: May increase risk
  evidence:
  - reference: PMID:35789269
    reference_title: "Increased Incidence of Hashimoto Thyroiditis in Selenium Deficiency: A Prospective 6-Year Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
    explanation: Prospective cohort data support selenium deficiency as a modifiable risk factor for Hashimoto's thyroiditis.
- name: Hepatitis C Virus Infection
  exposure_term:
    preferred_term: viral exposure
    term:
      id: ECTO:3000001
      label: exposure to virus
  influences_mechanisms:
  - target: Hepatitis C Virus-Associated Thyroid Immune Activation
    environmental_effect: PREDISPOSES
    causal_link_type: DIRECT
    description: >-
      Chronic hepatitis C virus (HCV) infection directly drives the antiviral
      immune activation captured by the intermediate node. Molecular mimicry and
      bystander activation are the usual proposals for how that then breaks
      tolerance, but the cited evidence is an association with chronic hepatitis
      C rather than a demonstration of either, and interferon treatment of that
      infection is itself thyrotoxic, which confounds the association.
    evidence:
    - reference: PMID:32107168
      reference_title: "Graves' disease: Epidemiology, genetic and environmental risk factors and viruses."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Many studies showed that HCV is associated with thyroid autoimmunity and hypothyroidism, in patients with chronic HCV hepatitis (CHC); a significant link has been shown also between HCV-related mixed cryoglobulinemia and risk for GD."
      explanation: >-
        Reports that hepatitis C virus is associated with thyroid autoimmunity
        and hypothyroidism in patients with chronic infection, an association
        rather than a mechanism.
  notes: >-
    HCV is the specific virus with human evidence; other candidate viruses are
    unverified here (see the pathophysiology node notes).
  evidence:
  - reference: PMID:32107168
    reference_title: "Graves' disease: Epidemiology, genetic and environmental risk factors and viruses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Many studies showed that HCV is associated with thyroid autoimmunity and hypothyroidism, in patients with chronic HCV hepatitis (CHC); a significant link has been shown also between HCV-related mixed cryoglobulinemia and risk for GD."
    explanation: Chronic hepatitis C virus infection is associated with thyroid autoimmunity and hypothyroidism.
- name: Low Vitamin D Intake and Cutaneous Synthesis
  exposure_term:
    preferred_term: low vitamin D exposure
    modifier: DECREASED
    term:
      id: ECTO:9000133
      label: exposure to vitamin D
  influences_mechanisms:
  - target: Vitamin D Deficiency
    environmental_effect: PREDISPOSES
    causal_link_type: DIRECT
    description: >-
      Inadequate dietary vitamin D and reduced cutaneous synthesis are the
      exposure that produces the systemic vitamin D-deficiency state (the
      grounded "Vitamin D Deficiency" state, MONDO:0100471). This is the weakest
      of the risk factors and the most exposed to reverse causation: the cited
      finding is that levels are lower in people who already have the disease,
      which cross-sectional data cannot separate from chronic illness lowering
      vitamin D. Recorded as PREDISPOSES rather than TRIGGERS for that reason,
      matching how the HCV edge is qualified.
    evidence:
    - reference: PMID:38542128
      reference_title: "Autoimmune Thyroiditis and Vitamin D."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people."
      explanation: >-
        INDIRECT because the snippet supports only half of what this edge
        asserts: it establishes that the deficiency state is associated with HT,
        but says nothing about dietary intake or cutaneous synthesis as the
        route to that state. It is also a cross-sectional comparison, so it does
        not establish direction.
  notes: >
    Low vitamin D status is consistently associated with HT; vitamin D has an
    immunomodulatory role promoting immune tolerance, and its deficiency is a
    candidate modifiable risk factor.
  evidence:
  - reference: PMID:38542128
    reference_title: "Autoimmune Thyroiditis and Vitamin D."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people."
    explanation: A 2024 review confirms vitamin D levels are significantly lower in HT patients, supporting deficiency as an associated environmental risk factor.
treatments:
- name: Levothyroxine
  description: >
    Thyroid hormone replacement therapy, the mainstay of treatment. It corrects
    the hormone deficiency by bypassing the destroyed gland but does not address
    the upstream autoimmunity or inflammation.
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Thyroid Hormone Deficiency
    treatment_effect: BYPASSES
    description: >
      Exogenous levothyroxine restores circulating T4/T3 and normalizes TSH,
      bypassing the hormone-synthesis capacity lost to glandular destruction.
    evidence:
    - reference: PMID:35235282
      reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Management includes thyroid hormone replacement, ideally levothyroxine."
      explanation: Levothyroxine replaces the deficient thyroid hormone output.
  evidence:
  - reference: PMID:35235282
    reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Management includes thyroid hormone replacement, ideally levothyroxine."
    explanation: Levothyroxine is standard hormone replacement therapy in hypothyroidism due to HT.
- name: Selenium Supplementation
  description: >
    Adjunctive selenium can lower thyroid autoantibody titers, but a 2024
    multicenter double-blind RCT found no quality-of-life benefit over placebo in
    LT4-treated autoimmune thyroiditis, illustrating a biomarker-outcome
    dissociation.
  target_mechanisms:
  - target: Autoimmune Thyroid Destruction
    treatment_effect: MODULATES
    description: >
      Selenium lowers TPO antibody titers, a serologic readout of the autoimmune
      process, without clearly altering clinical outcome.
    evidence:
    - reference: PMID:38243784
      reference_title: "Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In people with HT without THRT, selenium was effective and safe in lowering TSH, TPOAb, and MDA levels."
      explanation: Selenium modulates the autoimmune biomarker profile (TPOAb) in HT.
  evidence:
  - reference: PMID:38243784
    reference_title: "Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In people with HT without THRT, selenium was effective and safe in lowering TSH, TPOAb, and MDA levels."
    explanation: Meta-analysis supports selenium as a potential adjunct in selected HT patients.
  - reference: PMID:38215286
    reference_title: "Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "no difference in any of the ThyPRO-39 scales was found between the selenium group and the placebo group after 12 months of intervention"
    explanation: A 412-patient double-blind RCT found selenium gave no quality-of-life benefit over placebo despite biochemical antibody effects, tempering enthusiasm for routine use.
- name: Vitamin D Supplementation
  description: >
    Cholecalciferol supplementation in vitamin D-deficient HT patients can lower
    thyroid autoantibody titers; evidence is preliminary and further randomized
    trials are needed.
  target_mechanisms:
  - target: Autoimmune Thyroid Destruction
    treatment_effect: MODULATES
    description: >
      Vitamin D's immunomodulatory action is associated with reduced thyroid
      autoantibody titers in deficient patients.
    evidence:
    - reference: PMID:38542128
      reference_title: "Autoimmune Thyroiditis and Vitamin D."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "after the supplementation with cholecalciferol in patients with HT and vitamin D deficiency, thyroid autoantibody titers decreased significantly."
      explanation: Cholecalciferol supplementation reduces thyroid autoantibody titers in vitamin D-deficient HT patients.
  evidence:
  - reference: PMID:38542128
    reference_title: "Autoimmune Thyroiditis and Vitamin D."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "after the supplementation with cholecalciferol in patients with HT and vitamin D deficiency, thyroid autoantibody titers decreased significantly."
    explanation: Supports vitamin D repletion as an adjunct that lowers autoantibody titers in deficient HT patients.
- name: Monitoring
  description: Regular TSH monitoring to adjust replacement dose.
  evidence:
  - reference: PMID:35235282
    reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thyroid hormone should be titrated based on goal TSH values, symptoms, and potential treatment adverse effects."
    explanation: Ongoing TSH-based monitoring is required to titrate thyroid hormone replacement.
classifications:
  harrisons_chapter:
  - classification_value: ENDOCRINOLOGY_METABOLISM
    evidence:
    - reference: PMID:26235382
      reference_title: "Immunogenetics of autoimmune thyroid diseases: A comprehensive review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Both environmental and genetic triggers factor into the etiology of autoimmune thyroid disease (AITD), including Graves' disease (GD) and Hashimoto's thyroiditis (HT)."
      explanation: Hashimoto's thyroiditis is an autoimmune thyroid condition within endocrine system disorders.
    - reference: PMID:26235382
      reference_title: "Immunogenetics of autoimmune thyroid diseases: A comprehensive review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Both environmental and genetic triggers factor into the etiology of autoimmune thyroid disease (AITD), including Graves' disease (GD) and Hashimoto's thyroiditis (HT)."
      explanation: Directly classifies HT as autoimmune thyroid disease.
  - classification_value: IMMUNE_RHEUMATOLOGIC
    evidence:
    - reference: PMID:38731922
      reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
      explanation: Defines HT as an autoimmune disease with autoantibodies and lymphocytic infiltration.
datasets:
- accession: gtex:GTEx_v8_Thyroid
  title: GTEx v8 Thyroid tissue RNA-seq in Hashimoto case-control analysis
  description: >
    Bulk RNA-seq analysis of thyroid tissue from GTEx v8 used in a case-control
    comparison of histopathologically confirmed Hashimoto's thyroiditis and
    matched controls.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: thyroid gland
    term:
      id: UBERON:0002046
      label: thyroid gland
    tissue_term:
      preferred_term: thyroid gland
      term:
        id: UBERON:0002046
        label: thyroid gland
  sample_count: 104
  conditions:
  - Histopathologically confirmed Hashimoto's thyroiditis tissue
  - Matched non-Hashimoto thyroid tissue controls
  publication: PMID:33085325
  evidence:
  - reference: DOI:10.48188/so.6.9
    reference_title: "Transcriptome analysis of thyroid tissue in patients with Hashimoto’s disease using next-generation sequencing: case–control study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As part of a case–control design, we analyzed thyroid tissue RNA sequencing libraries from the Genotype-Tissue Expression Project (v8 release)."
    explanation: The dataset entry captures the GTEx v8 thyroid RNA-seq source used to compare Hashimoto and control thyroid tissue transcriptomes.
references:
- reference: DOI:10.1038/s41467-024-50192-5
  title: Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution
  findings: []
- reference: DOI:10.3389/fendo.2025.1584675
  title: Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
  findings: []
- reference: DOI:10.48188/so.6.9
  title: 'Transcriptome analysis of thyroid tissue in patients with Hashimoto’s disease using next-generation sequencing: case–control study'
  findings: []
📚

References & Deep Research

References

3
DOI:10.1038/s41467-024-50192-5
Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution
No top-level findings curated for this source.
DOI:10.3389/fendo.2025.1584675
Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
No top-level findings curated for this source.
DOI:10.48188/so.6.9
Transcriptome analysis of thyroid tissue in patients with Hashimoto’s disease using next-generation sequencing: case–control study
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Hashimoto's Thyroiditis
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 13

Key Pathophysiology Nodes

  • Autoimmune Thyroid Destruction
  • Lymphocytic Infiltration
  • Thyroid Hormone Deficiency
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1038/s41467-024-50192-5
  • DOI:10.3389/fendo.2025.1584675
  • DOI:10.48188/so.6.9
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 30 citations 2026-07-16T13:59:37.971253

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Hashimoto's Thyroiditis
  • MONDO ID: (if available)
  • Category: Complex

Research Objectives

Please provide a comprehensive research report on Hashimoto's Thyroiditis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Hashimoto’s Thyroiditis (HT): Comprehensive Disease Characteristics Report (2023–2024 emphasis)

Target disease

  • Disease name: Hashimoto’s thyroiditis (HT)
  • Category: Complex / polygenic autoimmune disease
  • MONDO ID: Not confirmed from the retrieved evidence in this run (should be programmatically looked up in MONDO; not inferred here).

Executive overview

Hashimoto’s thyroiditis is a chronic organ-specific autoimmune disease characterized by lymphocytic inflammation of the thyroid gland, circulating autoantibodies against thyroid antigens (notably thyroid peroxidase and thyroglobulin), characteristic ultrasound patterns, and a progressive course that commonly culminates in hypothyroidism requiring lifelong thyroid hormone replacement therapy (levothyroxine). (huwiler2024seleniumsupplementationin pages 1-2, kolanu2024fromantibodiesto pages 2-3)

A large 2024 GWAS meta-analysis in autoimmune thyroid disease (AITD; encompassing HT and related phenotypes) underscores extensive polygenicity and highlights genes involved in T-cell regulation; it identifies a rare start-codon/5′UTR LAG3 variant with a large effect size and functional evidence of reduced inhibitory checkpoint expression. (saevarsdottir2024startcodonvariant pages 7-8)

A 2024 Nature Communications spatial transcriptomics study provides high-resolution mechanistic insight into HT tissue architecture, emphasizing aberrant antigen presentation by thyroid follicular cells (CD74/MIF axis), immune infiltration (T cells, B cells, macrophages), inflammatory fibroblast programs, and vascular remodeling facilitating immune trafficking. (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 9-12, martinezhernandez2024unravelingthemolecular pages 13-14)

1. Disease information

1.1 What is the disease?

HT (also referred to as chronic autoimmune/lymphocytic thyroiditis) is described as a chronic autoimmune condition affecting the thyroid, driven by dysregulated T- and B-cell immune responses with thyroid infiltration by autoreactive lymphocytes and antibody production. (kolanu2024fromantibodiesto pages 2-3, huwiler2024seleniumsupplementationin pages 1-2)

1.2 Key identifiers and terminology

  • Synonyms: chronic autoimmune thyroiditis; chronic lymphocytic thyroiditis; autoimmune thyroiditis; Hashimoto disease. (huwiler2024seleniumsupplementationin pages 1-2, kolanu2024fromantibodiesto pages 1-2)
  • ICD-10 (suggested): E06.3 (autoimmune thyroiditis). (Not directly evidenced in retrieved texts; included as a standard clinical code suggestion—verify against ICD tables in implementation.)
  • MeSH (suggested): Hashimoto Disease. (Not directly evidenced in retrieved texts; verify via MeSH lookup in implementation.)

1.3 Evidence source type

The information in this report is derived from aggregated evidence sources (systematic reviews/meta-analyses, narrative reviews, human genetics studies, and spatial transcriptomics of human thyroid tissue), plus clinical trial registry entries (ClinicalTrials.gov). (huwiler2024seleniumsupplementationin pages 1-2, saevarsdottir2024startcodonvariant pages 7-8, martinezhernandez2024unravelingthemolecular pages 1-2, NCT05871957 chunk 1)

2. Etiology

2.1 Disease causal factors (current understanding)

HT etiology is multifactorial, involving genetic susceptibility and environmental triggers leading to breakdown of immune tolerance, lymphocytic infiltration, and thyroid tissue destruction. Reviews highlight genetic factors (e.g., HLA-DR, CTLA4) and environmental triggers such as excess dietary iodine and toxicant exposures. (kolanu2024fromantibodiesto pages 2-3)

2.2 Risk factors

  • Sex: Multiple sources emphasize a strong female predominance (reported as women being 4–10× more susceptible than men). (huwiler2024seleniumsupplementationin pages 1-2)
  • Micronutrient status: A 2024 review emphasizes that vitamin D levels are significantly lower in HT patients than controls and discusses supplementation as potentially antibody-lowering in deficient individuals. (duratrave2024autoimmunethyroiditisand pages 1-2)

2.3 Protective factors

Within the retrieved evidence, clear protective genetic variants or protective environmental exposures specific to HT were not explicitly identified; the main genetic evidence emphasizes risk loci and risk-increasing variants in immune regulatory genes. (saevarsdottir2024startcodonvariant pages 7-8)

2.4 Gene–environment interactions

The retrieved evidence supports the general framework of interaction among genetic influences, environmental triggers, and epigenetic effects in HT pathogenesis, but does not provide a specific, quantified gene–environment interaction effect size within the accessed texts. (duratrave2024autoimmunethyroiditisand pages 1-2)

3. Phenotypes

3.1 Core phenotypes and HPO suggestions

A diagnostic review describes common hypothyroid-associated symptoms including fatigue, weight gain, cold sensitivity, dry skin, and constipation. (kolanu2024fromantibodiesto pages 2-3)

Suggested HPO terms (examples) for knowledge base population: - Fatigue; Weight gain; Cold intolerance; Dry skin; Constipation; Hypothyroidism. (kolanu2024fromantibodiesto pages 2-3)

3.2 Laboratory abnormalities

Key laboratory features used in diagnosis include elevated TSH with decreased FT4/FT3 in overt hypothyroidism and detection of anti-TPO and anti-thyroglobulin antibodies as autoimmune markers. (kolanu2024fromantibodiesto pages 2-3)

3.3 Imaging and pathology phenotypes

  • Ultrasound: heterogeneous echotexture and diffuse hypoechogenicity. (kolanu2024fromantibodiesto pages 2-3)
  • Histopathology: lymphocytic infiltrates and germinal centers can be observed on fine-needle aspiration/biopsy; spatial transcriptomics corroborates immune-rich infiltrates with T cells, B cells, and inflammatory macrophages. (kolanu2024fromantibodiesto pages 2-3, martinezhernandez2024unravelingthemolecular pages 1-2)

3.4 Quality of life impact

HT can have persistent quality-of-life (QoL) burden even when biochemical targets are met; a 2024 review highlights that some patients report suboptimal HRQoL despite normalized TSH/T4. (huang2024traditionalchinesemedicine pages 4-5)

4. Genetic/molecular information

4.1 Genetic architecture (polygenic susceptibility)

A 2024 Nature Communications GWAS meta-analysis in AITD reports 110,945 cases and 1,084,290 controls, identifying 290 sequence variants at 225 loci (including 115 previously unreported), and emphasizes genes involved in T-cell regulation. (saevarsdottir2024startcodonvariant pages 7-8)

Abstract quote (genetics scale): “In a GWAS meta-analysis of 110,945 cases and 1,084,290 controls, 290 sequence variants at 225 loci are associated with AITD.” (saevarsdottir2024startcodonvariant pages 7-8)

4.2 Notable high-effect variant (LAG3)

The same study highlights a rare LAG3 variant (rs781745126-T) that creates a novel upstream start codon and is associated with increased AITD risk and functional reduction of LAG-3 expression. - Effect size: OR 3.42 with P = 2.2×10⁻¹⁶ (as reported in the abstract snippet). (saevarsdottir2024startcodonvariant pages 7-8) - Functional evidence: reduced LAG3 mRNA and surface expression on activated lymphocyte subsets and ~half plasma LAG-3 in heterozygotes; all three homozygous carriers had AITD. (saevarsdottir2024startcodonvariant pages 7-8)

4.3 Candidate genes outside MHC and immune regulation

The genetics evidence points to immune checkpoint and T-cell receptor signaling genes (e.g., LAG3 and ZAP70) as biologically coherent candidates linking inherited variation to immune dysregulation in AITD/HT-relevant phenotypes. (saevarsdottir2024startcodonvariant pages 7-8)

4.4 Epigenetic information

The accessed evidence notes epigenetic effects as part of the causal framework but does not provide specific methylation loci/histone marks within retrieved texts in this run. (duratrave2024autoimmunethyroiditisand pages 1-2)

5. Environmental information

5.1 Environmental and lifestyle contributors

A diagnostic-focused review lists environmental triggers including excess dietary iodine and toxicants as influences on disease development in susceptible individuals. (kolanu2024fromantibodiesto pages 2-3)

5.2 Infectious agents

No specific pathogen with causal attribution was supported by the retrieved evidence snippets in this run.

6. Mechanism / pathophysiology

6.1 Causal chain (immune dysregulation → tissue injury → hypothyroidism)

Across sources, a coherent mechanism emerges: 1) Genetic susceptibility and environmental triggers contribute to loss of tolerance and immune activation. (kolanu2024fromantibodiesto pages 2-3, duratrave2024autoimmunethyroiditisand pages 1-2, saevarsdottir2024startcodonvariant pages 7-8) 2) Thyroid-resident and infiltrating immune cells participate in antigen presentation and inflammatory amplification, including aberrant antigen presentation signatures in thyroid follicular cells. (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 9-12) 3) Chronic immune-mediated follicular injury and tissue remodeling progressively impair hormone synthesis, leading to hypothyroidism requiring replacement therapy. (huwiler2024seleniumsupplementationin pages 1-2, huang2024traditionalchinesemedicine pages 4-5)

6.2 Spatial transcriptomics (2024) and cell-type resolved mechanisms (high-authority primary research)

A 2024 Nature Communications study used spatial transcriptomics to resolve thyroid tissue architecture in AITD, including HT.

Key mechanistic findings relevant to HT: - Damaged thyroid follicular cells (TFCs) and antigen presentation: TFCs show upregulated CD74 and MIF, consistent with aberrant antigen presentation and immune communication. (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 12-13) - Immune infiltration: HT tissue demonstrates rich lymphocytic infiltrates (T cells, B cells) and inflammatory macrophages; borderline infiltrate zones show T-cell gene expression (e.g., TRAC/TRBC1/CD3D) and B-cell markers (MS4A1/CR2). (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 9-12) - Fibroblast programs and remodeling: inflammatory-associated fibroblasts (e.g., CXCL12+ and IGFBP6+ programs) are enriched in HT and linked to chemotaxis and extracellular matrix remodeling/destruction. (martinezhernandez2024unravelingthemolecular pages 13-14) - Vascular remodeling: endothelial features that facilitate immune trafficking are described, including specialized vessels (ACKR1+ high endothelial venules in infiltrated regions). (martinezhernandez2024unravelingthemolecular pages 9-12) - Cytokine amplification: IFN-γ and TNF-α can upregulate CD74 in TFCs and infiltrating immune cells, potentially amplifying ligand–receptor interactions and antigen-presentation pathways. (martinezhernandez2024unravelingthemolecular pages 9-12, martinezhernandez2024unravelingthemolecular pages 12-13)

Visual evidence (mechanistic schematic)

Figure 8 from Martínez-Hernández et al. summarizes an HT model with damaged CD74-high TFCs, a CD74/MIF loop, inflammatory fibroblast subtypes, and vascular/immune infiltration mechanisms. (martinezhernandez2024unravelingthemolecular media c4e4de12, martinezhernandez2024unravelingthemolecular media b04d5261)

6.3 Suggested ontology mappings for mechanisms

Examples aligned to evidence: - GO Biological Process (suggested): antigen processing and presentation via MHC class II; T cell activation; lymphocyte chemotaxis; extracellular matrix organization; regulation of vascular permeability. (martinezhernandez2024unravelingthemolecular pages 9-12, martinezhernandez2024unravelingthemolecular pages 13-14) - Cell Ontology (CL; suggested): thyroid follicular cell; T cell; B cell; macrophage; dendritic cell; fibroblast; endothelial cell. (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 9-12, martinezhernandez2024unravelingthemolecular pages 13-14)

7. Anatomical structures affected

7.1 Primary organ

  • Thyroid gland (primary site of inflammation, immune infiltration, tissue remodeling, and follicular injury). (huwiler2024seleniumsupplementationin pages 1-2, martinezhernandez2024unravelingthemolecular pages 1-2)

7.2 Tissue and cell level

Key implicated compartments/cell types in HT thyroid tissue include thyroid follicular epithelial cells, stromal fibroblast subtypes, endothelial cells, and infiltrating lymphocytes and macrophages. (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 13-14)

8. Temporal development

HT is typically chronic and insidious with variable progression, often culminating in hypothyroidism over time. (kolanu2024fromantibodiesto pages 1-2, huwiler2024seleniumsupplementationin pages 1-2)

9. Inheritance and population

9.1 Inheritance pattern

Evidence supports a polygenic/multifactorial inheritance architecture rather than single-gene Mendelian inheritance, based on large-scale GWAS results with many loci. (saevarsdottir2024startcodonvariant pages 7-8)

9.2 Epidemiology (statistics)

  • Global burden: HT has been described as affecting approximately 160 million people globally and is characterized as the most common cause of hypothyroidism in iodine-sufficient regions. (huwiler2024seleniumsupplementationin pages 1-2)
  • Sex ratio: women 4–10× more susceptible than men. (huwiler2024seleniumsupplementationin pages 1-2)
  • Incidence: approximately 0.3–1.5 per 1,000 persons reported in a 2024 review. (duratrave2024autoimmunethyroiditisand pages 1-2)
  • Prevalence: a 2024 diagnostic review reports global prevalence of 7.5%, rising to 11.4% in low- and middle-income countries (note: these are review-level estimates; confirm with population-based epidemiology during KB curation). (kolanu2024fromantibodiesto pages 1-2)

10. Diagnostics

10.1 Standard diagnostic elements

Evidence supports a multi-component approach: - Laboratory: elevated TSH and low FT4/FT3 in overt hypothyroidism; anti-TPO and anti-thyroglobulin antibodies as key autoimmune markers. (kolanu2024fromantibodiesto pages 2-3) - Seronegative HT: antibody-negative disease can occur (~5–10% reported), complicating diagnosis. (kolanu2024fromantibodiesto pages 1-2) - Ultrasound: heterogeneous echotexture and diffuse hypoechogenicity. (kolanu2024fromantibodiesto pages 2-3) - Histology/cytology: lymphocytic infiltrates and germinal centers may be observed; spatial transcriptomics confirms compartmentalized immune infiltration. (kolanu2024fromantibodiesto pages 2-3, martinezhernandez2024unravelingthemolecular pages 1-2)

10.2 Emerging diagnostics and technology

A 2024 diagnostic review describes emerging modalities (microRNA profiling, genetic markers, artificial intelligence approaches) as potential tools to improve diagnostic precision, particularly in complex or seronegative cases. (kolanu2024fromantibodiesto pages 5-6)

11. Outcome / prognosis

The retrieved evidence emphasizes chronicity and progression to hypothyroidism requiring lifelong therapy, but does not provide direct survival/mortality metrics or long-term disability statistics within accessed excerpts. (huwiler2024seleniumsupplementationin pages 1-2)

QoL: Persistent symptoms can occur despite biochemical normalization, motivating research into adjunctive strategies and patient-reported outcomes. (huang2024traditionalchinesemedicine pages 4-5)

12. Treatment

12.1 Standard-of-care pharmacotherapy

Levothyroxine (LT4) replacement is standard once hypothyroidism develops, typically lifelong, aiming to normalize serum TSH. (huwiler2024seleniumsupplementationin pages 1-2, huang2024traditionalchinesemedicine pages 4-5)

Clinical/therapeutic gap: LT4 corrects hormone deficiency but does not directly address upstream autoimmunity, inflammation, or oxidative stress; some patients report ongoing symptoms/HRQoL impairment despite normalized thyroid labs. (huang2024traditionalchinesemedicine pages 4-5)

12.2 Selenium supplementation (evidence synthesis + RCT)

2024 systematic review/meta-analysis (Thyroid; DOI:10.1089/thy.2023.0556; searched through Jan 2023; published Mar 2024): - TSH reduction in patients not on thyroid hormone replacement: SMD −0.21 (95% CI −0.43 to −0.02; 7 cohorts; n=869). (huwiler2024seleniumsupplementationin pages 1-2) - TPOAb reduction: SMD −0.96 (95% CI −1.36 to −0.56; 29 cohorts; n=2,358). (huwiler2024seleniumsupplementationin pages 1-2) - Adverse effects: OR 0.89 (95% CI 0.46 to 1.75; 16 cohorts; n=1,339), suggesting no clear increase in adverse events vs controls. (huwiler2024seleniumsupplementationin pages 1-2)

Abstract quote (meta-analysis results): “Our meta-analysis found that selenium supplementation decreased TSH in patients without THRT (SMD −0.21 …) [and] TPOAb (SMD −0.96 …) … Adverse effects were comparable between the intervention and control groups (OR 0.89 …).” (huwiler2024seleniumsupplementationin pages 1-2)

2024 multicenter double-blind RCT (European Thyroid Journal; Jan 2024; DOI:10.1530/etj-23-0175): - Population: 412 adults with autoimmune thyroiditis on LT4; 200 μg selenium/day vs placebo; 332 (81%) completed intervention. (larsen2024seleniumsupplementationand pages 1-2) - QoL: no between-group difference (ThyPRO-39 composite score 28.8 vs 28.0; P=0.602). (larsen2024seleniumsupplementationand pages 1-2) - Antibodies: lower TPOAb at 12 months in selenium group (1995 vs 2344 kIU/L; P=0.016). (larsen2024seleniumsupplementationand pages 1-2)

Interpretation (expert synthesis from evidence): Selenium supplementation appears to consistently lower antibody titers (biochemical effect), but high-quality RCT evidence indicates this does not necessarily translate to QoL benefit in LT4-treated hypothyroid autoimmune thyroiditis over 12 months, highlighting a biomarker–outcome dissociation relevant to clinical implementation. (larsen2024seleniumsupplementationand pages 1-2, huwiler2024seleniumsupplementationin pages 1-2)

12.3 Vitamin D (risk association and supplementation rationale)

A 2024 narrative review emphasizes vitamin D’s immunomodulatory role and reports that vitamin D levels are “significantly lower” in HT patients and that antibody titers “decreased significantly” after cholecalciferol supplementation in deficient patients, while calling for more randomized, placebo-controlled trials. (duratrave2024autoimmunethyroiditisand pages 1-2)

Abstract quote: “There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people. On the other hand, after the supplementation with cholecalciferol in patients with HT and vitamin D deficiency, thyroid autoantibody titers decreased significantly.” (duratrave2024autoimmunethyroiditisand pages 1-2)

12.4 Experimental/registry-listed interventional strategies (ClinicalTrials.gov)

  • Vitamin D as adjuvant (observational): NCT05871957; 30 female participants; vitamin D 2000 IU/day for 1 month; primary outcome TPOAb; secondary outcomes TgAb, FT3/FT4/TSH; registry indicates not-yet-recruiting at time of record. (NCT05871957 chunk 1)
  • Hydroxychloroquine (immunomodulation): NCT01760421; single-group interventional; 40 euthyroid adults; hydroxychloroquine 200 mg twice daily for 6 months; primary outcomes anti-TPO and anti-thyroglobulin antibodies; secondary outcomes include elastography and cytokines (IL-1/IL-6/TNF-α). (NCT01760421 chunk 1)
  • Dietary intervention: NCT05949671; compares gluten-free and Mediterranean dietary approaches over 12 weeks with dietitian support; enrollment reported as 40 in registry retrieval; primary outcome relates to autoimmune system effects. (NCT05949671 chunk 2)
  • Photobiomodulation therapy: NCT06735040; interventional study in HT patients on LT4; enrollment reported as 60; outcomes include depression/anxiety/fatigue measures over ~3 months. (NCT06735040 chunk 2)

13. Prevention

The retrieved evidence does not define an established primary prevention strategy for HT. Secondary prevention in practice centers on early detection of thyroid dysfunction and autoimmunity (TSH/FT4 and thyroid antibody testing) and timely management of hypothyroidism to prevent complications; this is implied by standard diagnostic/treatment paradigms rather than explicitly quantified in accessed excerpts. (kolanu2024fromantibodiesto pages 2-3, huwiler2024seleniumsupplementationin pages 1-2)

14. Other species / natural disease

No cross-species naturally occurring HT evidence was available in the retrieved excerpts for this run.

15. Model organisms

The retrieved excerpts did not provide specific model organism systems for HT, though mechanistic frameworks (immune tolerance breakdown, oxidative stress) are compatible with commonly used experimental autoimmune thyroiditis models (not evidenced here; do not infer without retrieval).

High-yield structured summary table (for knowledge base ingestion)

Category Item Details (include quantitative stats where available) Ontology/Identifier suggestions Key supporting sources
Disease overview / identifiers / synonyms Definition Autoimmune thyroid disease characterized by chronic lymphocytic inflammation of the thyroid, thyroid autoantibodies, progressive follicular damage, and frequent progression to hypothyroidism; standard treatment after hypothyroidism develops is lifelong levothyroxine replacement (huwiler2024seleniumsupplementationin pages 1-2, kolanu2024fromantibodiesto pages 2-3, huang2024traditionalchinesemedicine pages 4-5) MeSH: Hashimoto Disease; ICD-10: E06.3 Autoimmune thyroiditis; ICD-11: autoimmune thyroiditis; MONDO: Hashimoto thyroiditis if mapped in KB; UBERON: thyroid gland Huwiler 2024, DOI: 10.1089/thy.2023.0556; Kolanu 2024, DOI: 10.7759/cureus.54393; Huang 2024, DOI: 10.3390/antiox13070868
Disease overview / identifiers / synonyms Synonyms Common synonyms: chronic autoimmune thyroiditis, chronic lymphocytic thyroiditis, autoimmune thyroiditis, Hashimoto disease (huwiler2024seleniumsupplementationin pages 1-2, kolanu2024fromantibodiesto pages 1-2) MeSH synonym set; SNOMED/ICD cross-map as available Huwiler 2024, DOI: 10.1089/thy.2023.0556; Kolanu 2024, DOI: 10.7759/cureus.54393
Epidemiology Prevalence / incidence / sex Review sources report global prevalence about 7.5%, rising to 11.4% in LMICs; incidence about 0.3–1.5 per 1,000 persons; women affected 4–10× more often than men (kolanu2024fromantibodiesto pages 1-2, duratrave2024autoimmunethyroiditisand pages 1-2, huwiler2024seleniumsupplementationin pages 1-2) HPO modifier: female predominance; epidemiology fields in KB Kolanu 2024, DOI: 10.7759/cureus.54393; Durá-Travé 2024, DOI: 10.3390/ijms25063154; Huwiler 2024, DOI: 10.1089/thy.2023.0556
Epidemiology Age / natural history Often insidious, chronic, and progressive; incidence rises after childhood and commonly presents in adolescents/adults, with hypothyroidism emerging over time (kolanu2024fromantibodiesto pages 1-2, duratrave2024autoimmunethyroiditisand pages 1-2) HPO onset modifiers: adult onset / childhood onset variable Kolanu 2024, DOI: 10.7759/cureus.54393; Durá-Travé 2024, DOI: 10.3390/ijms25063154
Core diagnostic biomarkers Thyroid autoantibodies Anti-TPO (TPOAb) and anti-thyroglobulin (TgAb) are core serologic markers; seronegative disease occurs in about 5–10% of cases (kolanu2024fromantibodiesto pages 2-3, kolanu2024fromantibodiesto pages 1-2) LOINC/SNOMED for TPOAb and TgAb; HPO: Positive circulating thyroid autoantibody level Kolanu 2024, DOI: 10.7759/cureus.54393
Core diagnostic biomarkers Thyroid function tests Typical biochemical pattern: elevated TSH with low FT4/FT3 in overt hypothyroid disease; TSH/FT4 central to diagnosis and follow-up (kolanu2024fromantibodiesto pages 2-3, huang2024traditionalchinesemedicine pages 4-5) LOINC: TSH, free T4, free T3; HPO: Hypothyroidism, Abnormal thyroid-stimulating hormone level Kolanu 2024, DOI: 10.7759/cureus.54393; Huang 2024, DOI: 10.3390/antiox13070868
Core diagnostic biomarkers Common symptoms / phenotype anchors Frequent symptoms include fatigue, weight gain, cold intolerance, dry skin, constipation; reflect hypothyroid physiology rather than disease-specific autoimmunity (kolanu2024fromantibodiesto pages 2-3) HPO: Fatigue, Weight gain, Cold intolerance, Dry skin, Constipation, Hypothyroidism Kolanu 2024, DOI: 10.7759/cureus.54393
Imaging / histopathology Ultrasound Typical ultrasonography: heterogeneous echotexture and diffuse hypoechogenicity; characteristic but not fully specific (kolanu2024fromantibodiesto pages 2-3, huwiler2024seleniumsupplementationin pages 1-2) RadLex/SNOMED thyroid US findings; HPO: Abnormality of the thyroid gland Kolanu 2024, DOI: 10.7759/cureus.54393; Huwiler 2024, DOI: 10.1089/thy.2023.0556
Imaging / histopathology Histopathology Fine-needle aspiration / pathology may show dense lymphocytic infiltrates and germinal centers; thyroid tissue in HT contains T cells, B cells, macrophages around follicles (kolanu2024fromantibodiesto pages 2-3, martinezhernandez2024unravelingthemolecular pages 1-2) GO: lymphocyte activation, germinal center formation; CL: T cell, B cell, macrophage Kolanu 2024, DOI: 10.7759/cureus.54393; Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5
Genetics GWAS scale / susceptibility architecture Large AITD GWAS meta-analysis included 110,945 cases and 1,084,290 controls and identified 290 variants at 225 loci, including 115 previously unreported; highlights T-cell regulatory genes outside MHC (saevarsdottir2024startcodonvariant pages 7-8) GWAS Catalog entries; genes to prioritize: LAG3, ZAP70, HLA-region; disease inheritance: multifactorial/polygenic Saevarsdottir 2024, DOI: 10.1038/s41467-024-50007-7
Genetics High-impact variant Rare LAG3 5′UTR/start-codon variant rs781745126-T had the largest reported effect, OR 3.42, P = 2.2×10⁻¹⁶; carrier effect linked to reduced LAG-3 mRNA/surface expression and ~half plasma LAG-3 in heterozygotes; all 3 homozygotes had AITD (saevarsdottir2024startcodonvariant pages 7-8) HGNC: LAG3; variant: rs781745126-T; GO: negative regulation of T cell activation Saevarsdottir 2024, DOI: 10.1038/s41467-024-50007-7
Genetics Classic susceptibility genes Reviews also cite HLA-DR and CTLA4 among established susceptibility factors in HT/AITD (kolanu2024fromantibodiesto pages 2-3) HGNC: HLA-DR, CTLA4 Kolanu 2024, DOI: 10.7759/cureus.54393
Mechanisms / cell types Core immune mechanism HT is a T-cell-mediated autoimmune process with B-cell autoantibody production, thyroid lymphocytic infiltration, and progressive follicular injury leading to hypothyroidism (kolanu2024fromantibodiesto pages 2-3, duratrave2024autoimmunethyroiditisand pages 1-2) GO: immune response, antigen processing and presentation, T cell activation; CL: CD4-positive T cell, B cell Kolanu 2024, DOI: 10.7759/cureus.54393; Durá-Travé 2024, DOI: 10.3390/ijms25063154
Mechanisms / cell types Thyroid follicular cells / antigen presentation Spatial transcriptomics identified damaged, de-differentiated thyroid follicular cells (TFCs) with increased CD74 and MIF expression, consistent with aberrant MHC-II antigen presentation and a CD74/MIF autocrine loop promoting immune recruitment/repair signaling (martinezhernandez2024unravelingthemolecular pages 12-13, martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 13-14) CL: thyroid follicular cell; GO: antigen processing and presentation of peptide antigen via MHC class II, response to interferon-gamma Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5
Mechanisms / cell types Immune infiltrates HT tissue showed rich infiltrates with T cells, B lymphocytes, inflammatory macrophages, and myeloid cells; T-cell genes (TRAC, TRBC1, CD3D) and B-cell markers (MS4A1, CR2) were enriched in infiltrated zones (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 9-12) CL: T cell, B cell, macrophage, dendritic cell; GO: lymphocyte chemotaxis Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5
Mechanisms / cell types Fibroblast subtypes Two fibroblast programs were emphasized: inflammatory-associated fibroblasts, including CXCL12+ and IGFBP6+ populations linked to immune chemotaxis/ECM remodeling, and myofibroblast-like populations in interfollicular areas (martinezhernandez2024unravelingthemolecular pages 12-13, martinezhernandez2024unravelingthemolecular pages 13-14) CL: fibroblast, myofibroblast; GO: extracellular matrix organization, chemokine-mediated signaling pathway Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5
Mechanisms / cell types Endothelial / vascular changes Spatial data showed increased vascular permeability and specialized endothelial structures, including ACKR1+ high endothelial venules in HT infiltrates; broader AITD work also noted PLVAP+ fenestrated vessels (martinezhernandez2024unravelingthemolecular pages 9-12, martinezhernandez2024unravelingthemolecular pages 13-14) CL: endothelial cell; GO: angiogenesis, regulation of vascular permeability; UBERON: thyroid vasculature Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5
Mechanisms / cell types Cytokine context IFN-γ and TNF-α upregulate CD74 in TFCs and infiltrating immune cells, amplifying receptor-ligand interactions and antigen-presentation signaling (martinezhernandez2024unravelingthemolecular pages 12-13, martinezhernandez2024unravelingthemolecular pages 9-12) CHEBI: interferon gamma, tumor necrosis factor alpha; GO: cellular response to interferon-gamma, inflammatory response Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5
Environmental / risk factors Environment and micronutrients Reviews cite environmental triggers including excess dietary iodine and possible toxicant exposures; vitamin D deficiency is repeatedly associated with HT, though causality/intervention evidence remains incomplete (kolanu2024fromantibodiesto pages 2-3, duratrave2024autoimmunethyroiditisand pages 1-2) CHEBI: iodine, cholecalciferol; exposure ontology terms as available Kolanu 2024, DOI: 10.7759/cureus.54393; Durá-Travé 2024, DOI: 10.3390/ijms25063154
Standard treatment Levothyroxine replacement Standard of care for overt hypothyroidism due to HT is lifelong oral levothyroxine (LT4) to normalize TSH; therapy addresses hormone deficiency but not the upstream autoimmune process, inflammation, or oxidative stress (huwiler2024seleniumsupplementationin pages 1-2, huang2024traditionalchinesemedicine pages 4-5) MAXO: thyroid hormone replacement therapy, administration of levothyroxine; CHEBI: levothyroxine Huwiler 2024, DOI: 10.1089/thy.2023.0556; Huang 2024, DOI: 10.3390/antiox13070868
Adjunct / disease-modifying Selenium meta-analysis 2024 systematic review/meta-analysis of 35 studies found selenium lowered TSH in patients without thyroid hormone replacement (SMD −0.21, 95% CI −0.43 to −0.02; 7 cohorts, n=869), lowered TPOAb (SMD −0.96, 95% CI −1.36 to −0.56; 29 cohorts, n=2,358), lowered MDA (SMD −1.16; 3 cohorts, n=248), with adverse events similar to control (OR 0.89, 95% CI 0.46–1.75; 16 cohorts, n=1,339) (huwiler2024seleniumsupplementationin pages 1-2, huwiler2024seleniumsupplementationin pages 8-9, huwiler2024seleniumsupplementationin pages 11-12) MAXO: selenium supplementation; CHEBI: selenium, selenium-enriched yeast Huwiler 2024, DOI: 10.1089/thy.2023.0556
Adjunct / disease-modifying Selenium QoL RCT CATALYST RCT: 412 patients with autoimmune thyroiditis on LT4, 332 (81%) completed 12 months; 200 μg/day selenium vs placebo improved QoL similarly in both groups with no between-group difference in ThyPRO-39 composite score (28.8 vs 28.0, P=0.602). TPOAb was lower with selenium after 12 months (1995 vs 2344 kIU/L, P=0.016); no meaningful TSH difference (P=0.688) and no serious safety signal (larsen2024seleniumsupplementationand pages 1-2, larsen2024seleniumsupplementationand pages 6-8, larsen2024seleniumsupplementationand pages 8-10) MAXO: selenium supplementation, patient-reported outcome assessment Larsen 2024, DOI: 10.1530/etj-23-0175
Adjunct / disease-modifying Vitamin D Review-level evidence: HT patients often have lower vitamin D levels; some studies show reduced thyroid autoantibody titers after cholecalciferol in vitamin D-deficient HT, but authors stress need for more randomized double-blind placebo-controlled trials (duratrave2024autoimmunethyroiditisand pages 1-2) MAXO: vitamin D supplementation; CHEBI: cholecalciferol Durá-Travé 2024, DOI: 10.3390/ijms25063154
Experimental / ongoing trials Vitamin D adjuvant trial NCT05871957: prospective observational cohort; 30 female participants (18–60 years) with HT and hypothyroidism; vitamin D drops 2000 IU/day for 1 month; primary outcome TPOAb, secondary TgAb, FT3, FT4, TSH; status in registry chunk: not yet recruiting (NCT05871957 chunk 1, NCT05871957 chunk 2) NCT: NCT05871957; MAXO: vitamin D supplementation ClinicalTrials.gov, NCT05871957
Experimental / ongoing trials Hydroxychloroquine trial NCT01760421: completed single-group interventional study; 40 euthyroid adults; hydroxychloroquine 200 mg twice daily for 6 months; primary outcomes anti-TPO and anti-thyroglobulin; secondary outcomes included elastography, FT4/TSH, and inflammatory cytokines (IL-1, IL-6, TNF-α) (NCT01760421 chunk 1) NCT: NCT01760421; MAXO: hydroxychloroquine therapy ClinicalTrials.gov, NCT01760421
Experimental / ongoing trials Dietary intervention trial NCT05949671: interventional diet study in women with confirmed HT; total registry search reported 40 participants; compares gluten-free and Mediterranean diet approaches over 12 weeks with personalized dietitian support; primary focus is effect on the autoimmune system (NCT05949671 chunk 2) NCT: NCT05949671; MAXO: dietary modification, gluten-free diet, Mediterranean diet ClinicalTrials.gov, NCT05949671
Experimental / ongoing trials Photobiomodulation trial NCT06735040: interventional study in HT patients on LT4; registry search reported 60 participants; outcomes over about 3 months included depression, anxiety, and fatigue measures, reflecting symptom-focused adjunctive management (NCT06735040 chunk 2) NCT: NCT06735040; MAXO: photobiomodulation therapy ClinicalTrials.gov, NCT06735040
Visual / reference resource Mechanistic figure Figure 8 from the 2024 spatial transcriptomics study provides a concise mechanistic map of HT: damaged CD74-high TFCs, CD74/MIF loop, inflammatory fibroblasts, endothelial remodeling, and immune infiltration (martinezhernandez2024unravelingthemolecular media c4e4de12, martinezhernandez2024unravelingthemolecular media b04d5261) Evidence figure linkable in KB; GO/CL mapping support Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5

Table: This table summarizes high-yield disease-characteristic facts for a Hashimoto’s thyroiditis knowledge-base entry, emphasizing 2023–2024 evidence, ontology suggestions, quantitative findings, and trial identifiers.

URLs, publication dates, and authority notes (key 2024 sources used)

  • Martínez-Hernández et al., Nature Communications, July 2024. Spatial transcriptomics of AITD at tissue resolution. https://doi.org/10.1038/s41467-024-50192-5 (martinezhernandez2024unravelingthemolecular pages 1-2)
  • Saevarsdottir et al., Nature Communications, July 2024. AITD GWAS meta-analysis + functional multiomics; LAG3 variant. https://doi.org/10.1038/s41467-024-50007-7 (saevarsdottir2024startcodonvariant pages 7-8)
  • Huwiler et al., Thyroid, March 2024. Selenium systematic review/meta-analysis. https://doi.org/10.1089/thy.2023.0556 (huwiler2024seleniumsupplementationin pages 1-2)
  • Larsen et al., European Thyroid Journal, January 2024. Selenium RCT (CATALYST) in autoimmune thyroiditis on LT4. https://doi.org/10.1530/etj-23-0175 (larsen2024seleniumsupplementationand pages 1-2)
  • Durá-Travé & Gallinas-Victoriano, International Journal of Molecular Sciences, March 2024. Vitamin D and autoimmune thyroiditis. https://doi.org/10.3390/ijms25063154 (duratrave2024autoimmunethyroiditisand pages 1-2)
  • Kolanu et al., Cureus, February 2024. Diagnostic challenges and emerging AI. https://doi.org/10.7759/cureus.54393 (kolanu2024fromantibodiesto pages 2-3)
  • ClinicalTrials.gov entries: NCT05871957; NCT01760421; NCT05949671; NCT06735040. (NCT05871957 chunk 1, NCT01760421 chunk 1, NCT05949671 chunk 2, NCT06735040 chunk 2)

References

  1. (huwiler2024seleniumsupplementationin pages 1-2): Valentina V. Huwiler, Stephanie Maissen-Abgottspon, Zeno Stanga, Stefan Mühlebach, Roman Trepp, Lia Bally, and Arjola Bano. Selenium supplementation in patients with hashimoto thyroiditis: a systematic review and meta-analysis of randomized clinical trials. Mar 2024. URL: https://doi.org/10.1089/thy.2023.0556, doi:10.1089/thy.2023.0556. This article has 132 citations.

  2. (kolanu2024fromantibodiesto pages 2-3): Nikhil Deep Kolanu, Naimel Ansar Awan, Ayesha Imran Butt, Taufiqa Reza, Mohammed Khaleel I.KH. Almadhoun, Taher Janoowala, Syed Faqeer Hussain Bokhari, Zukhruf Zain, Tanzila Sharif, Lokesh Chauhan, and Jinal Choudhari. From antibodies to artificial intelligence: a comprehensive review of diagnostic challenges in hashimoto’s thyroiditis. Cureus, Feb 2024. URL: https://doi.org/10.7759/cureus.54393, doi:10.7759/cureus.54393. This article has 19 citations.

  3. (saevarsdottir2024startcodonvariant pages 7-8): Saedis Saevarsdottir, Kristbjörg Bjarnadottir, Thorsteinn Markusson, Jonas Berglund, Thorunn A. Olafsdottir, Gisli H. Halldorsson, Gudrun Rutsdottir, Kristbjorg Gunnarsdottir, Asgeir Orn Arnthorsson, Sigrun H. Lund, Lilja Stefansdottir, Julius Gudmundsson, Ari J. Johannesson, Arni Sturluson, Asmundur Oddsson, Bjarni Halldorsson, Björn R. Ludviksson, Egil Ferkingstad, Erna V. Ivarsdottir, Gardar Sveinbjornsson, Gerdur Grondal, Gisli Masson, Grimur Hjorleifsson Eldjarn, Gudmundur A. Thorisson, Katla Kristjansdottir, Kirk U. Knowlton, Kristjan H. S. Moore, Sigurjon A. Gudjonsson, Solvi Rognvaldsson, Stacey Knight, Lincoln D. Nadauld, Hilma Holm, Olafur T. Magnusson, Patrick Sulem, Daniel F. Gudbjartsson, Thorunn Rafnar, Gudmar Thorleifsson, Pall Melsted, Gudmundur L. Norddahl, Ingileif Jonsdottir, and Kari Stefansson. Start codon variant in lag3 is associated with decreased lag-3 expression and increased risk of autoimmune thyroid disease. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50007-7, doi:10.1038/s41467-024-50007-7. This article has 14 citations and is from a highest quality peer-reviewed journal.

  4. (martinezhernandez2024unravelingthemolecular pages 1-2): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.

  5. (martinezhernandez2024unravelingthemolecular pages 9-12): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.

  6. (martinezhernandez2024unravelingthemolecular pages 13-14): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.

  7. (kolanu2024fromantibodiesto pages 1-2): Nikhil Deep Kolanu, Naimel Ansar Awan, Ayesha Imran Butt, Taufiqa Reza, Mohammed Khaleel I.KH. Almadhoun, Taher Janoowala, Syed Faqeer Hussain Bokhari, Zukhruf Zain, Tanzila Sharif, Lokesh Chauhan, and Jinal Choudhari. From antibodies to artificial intelligence: a comprehensive review of diagnostic challenges in hashimoto’s thyroiditis. Cureus, Feb 2024. URL: https://doi.org/10.7759/cureus.54393, doi:10.7759/cureus.54393. This article has 19 citations.

  8. (NCT05871957 chunk 1): Adjuvant Therapeutic Effect of Vitamin D on Hashimoto's Thyroiditis. Qianfoshan Hospital. 2023. ClinicalTrials.gov Identifier: NCT05871957

  9. (duratrave2024autoimmunethyroiditisand pages 1-2): Teodoro Durá-Travé and Fidel Gallinas-Victoriano. Autoimmune thyroiditis and vitamin d. International Journal of Molecular Sciences, 25:3154, Mar 2024. URL: https://doi.org/10.3390/ijms25063154, doi:10.3390/ijms25063154. This article has 78 citations.

  10. (huang2024traditionalchinesemedicine pages 4-5): Sheng Huang, Panos G. Ziros, Dionysios V. Chartoumpekis, Georgios Psarias, Leonidas Duntas, Xinhe Zuo, Xinyi Li, Zhiguo Ding, and Gerasimos P. Sykiotis. Traditional chinese medicine for hashimoto’s thyroiditis: focus on selenium and antioxidant phytochemicals. Antioxidants, 13:868, Jul 2024. URL: https://doi.org/10.3390/antiox13070868, doi:10.3390/antiox13070868. This article has 14 citations.

  11. (martinezhernandez2024unravelingthemolecular pages 12-13): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.

  12. (martinezhernandez2024unravelingthemolecular media c4e4de12): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.

  13. (martinezhernandez2024unravelingthemolecular media b04d5261): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.

  14. (kolanu2024fromantibodiesto pages 5-6): Nikhil Deep Kolanu, Naimel Ansar Awan, Ayesha Imran Butt, Taufiqa Reza, Mohammed Khaleel I.KH. Almadhoun, Taher Janoowala, Syed Faqeer Hussain Bokhari, Zukhruf Zain, Tanzila Sharif, Lokesh Chauhan, and Jinal Choudhari. From antibodies to artificial intelligence: a comprehensive review of diagnostic challenges in hashimoto’s thyroiditis. Cureus, Feb 2024. URL: https://doi.org/10.7759/cureus.54393, doi:10.7759/cureus.54393. This article has 19 citations.

  15. (larsen2024seleniumsupplementationand pages 1-2): Camilla Bøgelund Larsen, Kristian Hillert Winther, Per Karkov Cramon, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Nils Jakob Knudsen, Jakob Bue Bjorner, Lutz Schomburg, Kamil Demircan, Thilo Samson Chillon, Jeppe Gram, Stinus Gadegaard Hansen, Frans Brandt, Birte Nygaard, Torquil Watt, Laszlo Hegedüs, and Steen Joop Bonnema. Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism. European Thyroid Journal, Jan 2024. URL: https://doi.org/10.1530/etj-23-0175, doi:10.1530/etj-23-0175. This article has 40 citations and is from a peer-reviewed journal.

  16. (NCT01760421 chunk 1): The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis. National Taiwan University Hospital. 2011. ClinicalTrials.gov Identifier: NCT01760421

  17. (NCT05949671 chunk 2): Evaluation of the Effect of Gluten-Free Diet and Mediterranean Diet. Acibadem University. 2021. ClinicalTrials.gov Identifier: NCT05949671

  18. (NCT06735040 chunk 2): Sümeyye TUNÇ. Effect of Photobiomodulation Therapy in Patients With Hashimoto's Thyroiditis. Istanbul Medipol University Hospital. 2021. ClinicalTrials.gov Identifier: NCT06735040

  19. (huwiler2024seleniumsupplementationin pages 8-9): Valentina V. Huwiler, Stephanie Maissen-Abgottspon, Zeno Stanga, Stefan Mühlebach, Roman Trepp, Lia Bally, and Arjola Bano. Selenium supplementation in patients with hashimoto thyroiditis: a systematic review and meta-analysis of randomized clinical trials. Mar 2024. URL: https://doi.org/10.1089/thy.2023.0556, doi:10.1089/thy.2023.0556. This article has 132 citations.

  20. (huwiler2024seleniumsupplementationin pages 11-12): Valentina V. Huwiler, Stephanie Maissen-Abgottspon, Zeno Stanga, Stefan Mühlebach, Roman Trepp, Lia Bally, and Arjola Bano. Selenium supplementation in patients with hashimoto thyroiditis: a systematic review and meta-analysis of randomized clinical trials. Mar 2024. URL: https://doi.org/10.1089/thy.2023.0556, doi:10.1089/thy.2023.0556. This article has 132 citations.

  21. (larsen2024seleniumsupplementationand pages 6-8): Camilla Bøgelund Larsen, Kristian Hillert Winther, Per Karkov Cramon, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Nils Jakob Knudsen, Jakob Bue Bjorner, Lutz Schomburg, Kamil Demircan, Thilo Samson Chillon, Jeppe Gram, Stinus Gadegaard Hansen, Frans Brandt, Birte Nygaard, Torquil Watt, Laszlo Hegedüs, and Steen Joop Bonnema. Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism. European Thyroid Journal, Jan 2024. URL: https://doi.org/10.1530/etj-23-0175, doi:10.1530/etj-23-0175. This article has 40 citations and is from a peer-reviewed journal.

  22. (larsen2024seleniumsupplementationand pages 8-10): Camilla Bøgelund Larsen, Kristian Hillert Winther, Per Karkov Cramon, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Nils Jakob Knudsen, Jakob Bue Bjorner, Lutz Schomburg, Kamil Demircan, Thilo Samson Chillon, Jeppe Gram, Stinus Gadegaard Hansen, Frans Brandt, Birte Nygaard, Torquil Watt, Laszlo Hegedüs, and Steen Joop Bonnema. Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism. European Thyroid Journal, Jan 2024. URL: https://doi.org/10.1530/etj-23-0175, doi:10.1530/etj-23-0175. This article has 40 citations and is from a peer-reviewed journal.

  23. (NCT05871957 chunk 2): Adjuvant Therapeutic Effect of Vitamin D on Hashimoto's Thyroiditis. Qianfoshan Hospital. 2023. ClinicalTrials.gov Identifier: NCT05871957

Artifacts